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Chemokine receptor CCR5 and the mu opioid receptor (MOR) undergo receptor 
dimerization in the membranes of neuronal cells.  CCR5 is a co-receptor for the human 
immunodeficiency virus's (HIV) entry into host cells and is therefore a potential target of small 
molecule antagonists for therapeutic purposes.  Activation of MOR is believed to both increase 
CCR5 expression levels and increase HIV viral entry into neuronal cells by dimerizing with 
CCR5.  It is therefore of interest to develop chemical probes that target the CCR5-MOR 
interaction.  
A bivalent ligand containing both CCR5 and MOR pharmacophores was previously 
designed and synthesized to study the CCR-MOR heterodimer and its relavence to NeuroAIDS. 
In this work, two more bivalent ligands with structural modifications in spacer length were 
designed and synthesized along with a number of control compounds.  The structure-activity 
relationships of these compounds were studied in radio-ligand binding assays and cell-based 
functional assays.  Furthermore, the original bivalent ligand and the two new ligands were 
subjected to conformational analysis.
In conclusion, bivalent ligands were synthesized to target the putative CCR5-MOR 
heterodimer, and these molecules were subjected to in vitro and in silico studies.  The two new 
bivalent molecules bound to the MOR with an activity similar to that of naltrexone, an MOR 
antagonist, while they bound to CCR5 with lower affinity compared to maraviroc, a CCR5 
antagonist, indicating that further structural modification to the CCR5 portion of the bivalent 
ligand is necessary.  Also, further work is underway to verify that the two novel bivalent 
compounds can indeed recognize to the CCR5-MOR heterodimer with reasonable potency.
1.  Introduction
1.1 Chemokine Receptor CCR5
1.1.1 Function of Chemokines and Chemokine Receptors 
Chemokines, or chemotactic cytokines, are a small group of signal proteins that act as mediators 
in the process of inflammation.1–6 When inflammation is induced in living tissue, mediators are released 
into the blood-stream; these mediators (i.e., cytokines) then bind to proteins on the membranes of 
leukocytes, or white blood cells, which are recruited to the site of inflammation in order to protect the 
body from unwanted bacteria.1–3 Chemokine receptors are among several proteins on the surface of 
leukocyte cell membranes that interact with the mediators of inflammation.3
There are about 50 known and classified chemokines.3,6 Four families of chemokines exist and 
they are grouped based on the conserved cysteine residues found at the N-terminal of the peptides: CC 
chemokine, C chemokine, CXC chemokine and CX3C chemokine.3 In the CC family, the cysteine 
residues are adjacent to each other.3 In the C family, on the other hand, one of the cysteine residues is 
missing.3 For the CXC and CX3C families, the two cysteines are separated by one and three variable 
residues, respectively.3 Most of the known chemokines fall into the CC and CXC families and to date 
there are only 18 known chemokine receptors.3
1.1.2 Chemokine Receptor Type CCR5 and GPCRs
Chemokine receptors fall into a superfamily of membranous proteins called G protein-coupled 
receptors (GPCR).3–6 These proteins are characterized by their canonical seven transmembrane (TM) 
helices which bind to heterotrimeric G proteins to mediate responses from outside signal molecules. 
The GPCR superfamily of proteins includes 791 genes encoding for six different receptor subtypes, 
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most of which belong to the rhodopsin-like receptor subtype, or the class A subtype.3 Chemokine 
receptors are all within the class A GPCR subtype.3 Chemokine receptors are classified based upon 
which chemokines bind to them; thus there are CC, CXC, XC and CX3C receptors.3 Also, many of the 
chemokine receptors are promiscuous and bind to different chemokines within a chemokine family.1–5 
For example, a CC receptor can bind to many different CC chemokines.  This allows for redundancy of 
response, given that many different chemokines within a family can elicit the same response at the 
same receptor.
Figure 1.  A canonical representation of a GPCR.7
When a chemokine binds to a chemokine receptor, it starts an activation cycle that is 
characteristic for all GPCRs.3 That is, when a resting chemokine receptor is activated by an agonist, the 
bound inactive heterotrimeric G protein, which is composed of guanosine diphosphate (GDP) bound 
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Gα and Gβγ subunits, is converted to an active G protein.8–14   This protein becomes active by 
exchanging GDP for guanosine triphosphate (GTP), whereupon the Gα and Gβγ subunits dissociate 
from each other.11, 12, 14 These subunits then go on to activate or inhibit different downstream signaling 
pathways through the recruitment of various second-messenger proteins such as adenylyl cyclase and 
phospholipase-C.11, 12 These subunits remain active until the GTP is hydrolyzed back to GDP, 
whereupon the Gα and Gβγ subunits re-associate with each other and travel back to the resting-state 
GPCR.11, 12, 14
Looking at agonist-bound crystal structures of GPCRs, several structural changes between 
activated and unactivated GPCRs are noteworthy.9, 10, 15 For instance, there are several changes in the 
transmembrane helices upon agonist binding.9, 10 These include an outward movement of TM6 and a 
rearrangement between TM5 and TM7.9, 10 For particular amino acid residues, there is a disruption of a 
conserved ionic lock between aspartate/glutamate and arginine of the DRY sequence and the movement 
of tryptophan6.48 from TM7 to TM5, both of which allow for the facilitation of the receptor to a more 
active state.10 However, it should be noted that these structural changes have not been observed in every 
GPCR to date.
Chemokine receptor type CCR5 (CCR5) is a chemokine receptor that undergoes such 
conformational changes when it binds to chemokines.8, 16, 17 CCR5 is expressed on leukocytes and is 
activated by several chemokines, including, but not limited to, macrophage inflammatory protein-1α 
(MIP-1α), MIP-1β and regulated upon activation normally T-cell expressed and secreted (RANTES).8 
Activation of CCR5 by these chemokines leads to several signaling cascades that are characteristic of 
many GPCRs. 
1.1.3 CCR5 Downstream Effects and Regulation
CCR5 induces several downstream effects upon agonist binding.16–18 These include intracellular 
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Ca2+ release from the endoplasmic reticulum (ER), activating MAP kinases and inhibiting adenylyl 
cyclase.16 CCR5 is also promiscuous for the types of Gα subunits it activates, as it activates both Gαi 
and Gαq.17 Because CCR5 couples to two different G proteins, it allows CCR5 to activate more than 
one signaling pathway.17 For the pathway involving Gαi, the Gα subunit inhibits adenylyl cyclase.17 
This reduces the production of cAMP from ATP.  For the pathway involving Gαq, phospholipase C 
(PLC) becomes activate and produces diacyl glycerol (DAG) and inositol triphosphate (IP3) by 
hydrolyzing phosphatidylinositol 4,5-biphosphate (PIP2).17 DAG goes on to activate protein kinase C 
(PKC), whereas IP3 activates calcium channels on the ER and causes the amount of intracellular 
calcium to increase.17 The Gβγ subunit also plays a roll in downstream signaling by activating PLC, 
which, as already mentioned, increases the production of intracellular calcium.17
Figure 2. The CCR5 signaling cascade leads to multiple downstream effects.  
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GPCRs such as CCR5 are regulated by a variety of mechanisms; these include desensitization 
of the receptor, internalization of the receptor and recycling/degradation of the receptor.19, 20 
Desensitization of the receptor reduces its response to external stimuli, whereas internalization and 
recycling/degradation of the receptor reduce the amount of receptors present on the cell's membrane.19, 
20 Repeated activation of the receptor by agonists leads to desensitization through the phosphorylation 
of the GPCR's C-terminus; the protein becomes desensitized by the phosphorylation of four serine 
residues – S336, S337, S342 and S349 – by G protein-coupled receptor kinases (GRKs).20 For the 
process of internalization and recycling/degradation of the receptor, the phosphorylated serine residues 
increase the binding affinity of GPCRs for β-arrestin.20 When β-arrestin binds to a GPCR, it blocks G 
proteins from binding to it, thereby eliminating the GPCR's downstream signaling pathways.20 β-
arrestin can then complex with adaptor complex 2 (AP2) and clathrin.20 This complex causes the GPCR 
to internalize by endocytocis, whereupon it is either degraded by lysosomal proteins or recycled back to 
the membrane.20 Also, β-arrestins can activate several cascades by activating mitogen-activated protein 
kinases (MAPKs) and non-receptor tyrosine kinases (nRTKs).19, 20 Furthermore, a GPCR can be 
desensitized through the binding of  a certain ligand which reduces the GPCR's affinity for other 
ligands (this ligand varies depending on the GPCR to which it binds).19
1.1.4 GPCRs as Drug Targets and CCR5 in HIV-Associated Diseases
GPCRs are among the most targeted proteins for therapeutic purposes.21 In fact, more than 30% 
of all drugs designed in the last five years target GPCRs.22, 23 One of the disease states associated with 
GPCRs is cancer.24, 25 When a gene encoding for a GPCR has been mutated in such a way so as to 
produce a constitutively active protein, very often the signaling pathways downstream of that GPCR 
remain active.24, 25 This leads to the growth and differentiation of cells in which the GPCR is expressed. 
CCR5 is also associated with breasts cancer, ovarian cancer and prostate cancer.25 – 30 
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CCR5 is also associated with the human immunodeficiency virus (HIV).31 In fact, CCR5 is 
among the most targeted proteins in HIV therapeutics.31 This is because CCR5 acts as a vital co-
receptor in HIV invasion into host cells.31–33 Although CCR5 is predominantly expressed on leukocytes, 
in particular helper-T cells, it is also expressed on microglia and astroglia, and the infection of these 
cells contributes to the degradation of neurons..31 CCR5's association with HIV-invasion in host cells is 
described in more detail below this section.
1.1.5 CCR5's Association with HIV/AIDS
HIV causes the destruction of lymphocytes expressing cluster of differentiation 4 (CD4) 
membranous proteins.31 This leads to an immunocompromised disease known as acquired 
immunodeficiency syndrome (AIDS).31 In particular, this disease is most prevalent in developing 
countries in sub-Saharan Africa, and most mortalities from AIDS come from this region.27 About 1.6 
million people died from AIDS in 2012 according to the Center for Disease Control, and more than 2 
million are infected per year on average.31 The virus consists of a single strand of RNA necessary to 
encode viral enzymatic and structural proteins.31 
The virus invades host cells by using a viral envelop protein (Env) consisting of three 
glycoprotein subunits that bind to and interact with CD4.31 This glycoprotein consists of gp41 and 
gp120 subunits.31 A conformational change in the gp120 subunit upon CD4 binding allows it to interact 
with CCR5, which acts as a co-receptor in HIV viral entry.31 Once this three-protein complex is formed 
between CD4, gp120 and CCR5, another conformational change occurs in the Env protein that allows 
gp41 to insert itself into the host cell's membrane.31 This further facilitates viral entry into host cells. 
However, although CCR5 helps the HIV virus invade host cells, receptor CD4 is the main receptor of 
HIV.
The importance of CCR5 in HIV infection is demonstrated by the increased resistance that 
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people with homozygous CCR5 recessive alleles have to HIV viral invasion.35, 36 That is, if an 
individual has mutations in both CCR5-encoding genes, then HIV cannot use CCR5 as a co-receptor to 
invade host cells.  Mutations to CCR5 prevent the gp120 subunit of the Env protein from binding to it 
and facilitating viral entry.
Figure 3.  CCR5 and CXCR4 act as co-receptors in helping facilitate viral entry into host cells.37
1.1.6 Small molecules targeting CCR5
Pharmaceutical companies have been trying to develop small-molecule antagonists that target 
CCR5, mostly because of its involvement in HIV host cell invasion.39–42 These efforts have led to the 
approval of maraviroc (1) by the FDA to treat retroviral infections.39–41 Maraviroc was developed by 
Pfizer from a high-throughput screening (HTS) hit in the early 2000's.39–41 The initial compound showed 
a high affinity for CCR5 (Ki = 4 nM) but did not produce any antiretroviral activity.39, 40 Therefore, the 
compound was modified using structure-activity relationship (SAR) techniques, and this led to a 
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molecule, maraviroc, that had an IC50 = 2 nM for the CCR5 receptor. In fact, clinical studies indicated 
that two daily doses of 25 mg maraviroc were more effective at slowing the progression of HIV-1 host 
cell invasion than the current leading anti-HIV-1 drug at the time.41
Table 1.  Small molecule CCR5 antagonists
Name Structure Status
Maraviroc NN
N
N
HN
O
F
F
1
FDA-approved
Vicriviroc
F3C
O
N N N
O
N
N
2
Terminated
Aplaviroc
O
O
N
NH
N
OHO
3
Terminated
TAK-779
N
H
N
O
O
4
Modified form in Phase 
II Clinical Trials
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Two other anti-HIV-1 drugs that showed very good antagonism for the CCR5 receptor were 
vicriviroc (2) and aplaviroc (3).41 However, both these drugs were discontinued during Phase III 
clinical trials because vicriviroc had poor bioavailability and aplaviroc showed severe hepatotoxicity.41, 
43 To date, maraviroc is considered the most effective drug for inhibiting the progression of HIV 
through antagonism of CCR5.44 However, Schering-Plough has reported the development of a second-
generation CCR5 antagonist known as SCH532706.44 As of right now, SCH532706 is in Phase III 
clinical trials, and the molecule shows both high anti-HIV-1 activity and good bioavailability.44
Before the development of maraviroc and other second-generation CCR5 antagonists, TAK-779 
(4), the first known CCR5 antagonist, was reported by Takeda Chemicals in 1999.45 The molecule was 
shown to inhibit HIV-1 entry with an IC50 = 3.7 nM.45 The molecule was also shown to have a very high 
affinity for CCR5 in a radioligand binding assay (Ki = 1.4 nM).45 However, the molecule's development 
was discontinued because of both poor oral bioavailability and toxicity issues, although modification to 
improve oral bioavailability led to another CCR5 antagonist which is currently in phase II clinical 
trials.44
1.2 The Mu Opioid Receptor 
1.2.1 Opioid Receptors
Opioid receptors are the site of action for morphine and its derivatives.46 The name “opioid” 
comes from the fact that morphine, the first known exogenous agonist of this class of receptors, was 
isolated from opium poppy extracts.46 Opioid receptors, like chemokine receptors, are GPCRs.46 To date 
there are four known opioid receptors that have been crystallized: δ opioid receptor (DOR), κ opioid 
receptor (KOR), µ opioid receptor (MOR) and nociception/orphanin opioid receptor (NOR).47–50 Two of 
these receptors – KOR and MOR – were named according to the opiates to which they bound: 
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morphine and ketocyclazocine, respectively.47, 49 There are also small endogenous peptides that bind to 
opiate receptors; they include enkephalins and dynorphins.51–55 
When opiates bind to their MOR, they elicit analgesic and anti-diarrheal effects.51, 52 This gives 
them a high therapeutical potential, especially in settings requiring fast-acting pain-relief.  However, 
although opiates elicit analgesic and anti-diarrheal effects upon binding to their receptors and produce 
numerous therapeutic results, there are certain unwanted side-effects when taking them.56–59 For 
instance, the molecule morphine has a high potential for abuse because of its addictive nature.56–59 Much 
of the work that has been done modifying opiates, therefore, has focused on reducing this addictive 
potential.60 Also, it has been discovered that while the three traditional opioid receptors – DOR, KOR 
and MOR – each produce analgesic effects, the neural response that each receptor controls is 
different.52 DOR affects anxiety and depressive behaviors, KOR produces dysphoria and MOR control 
euphoric feelings.52
1.2.2 Mu Opioid Receptor Structure and Downstream Signaling
As mentioned before, opioid receptors are included in the GPCR superfamily.61 Thus, the mu 
opioid receptor shares many structural features with other common GPCRs, most importantly the seven 
TM helices.  Of note, MOR has a β-hairpin in extracellular loop (EL) 2.61
Because MOR is a GPCR, it shares many of the same signaling mechanisms as CCR5, such as 
the activation of a heterotrimeric G protein.61 However, because it is coupled to a different G protein 
(i.e., Gαi/o) from CCR5, it causes the activation of different downstream signaling pathways upon 
agonist binding.61 For instance, Gαi inhibits adenylyl cyclase and activates K+ channels, whereas Gαo 
inhibits Ca2+ channels (and thus causes the concentration of intracellular calcium to decrease).61 
However, because the Gβγ subunit activates PLC and thus increases the concentration of intracellular 
calcium, agonist binding to MOR can also cause an effect opposite from that of Gαo activation.  This 
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creates a negative feedback loop that allows for fine-tuning of downstream signaling.
As with the CCR5 receptor, MOR activity is also regulated: desensitization and protein-based 
trafficking also occur so as to limit the amount of receptor activity on a cell's membrane.61 
Phosphorylation of the serine residues located at the protein's C-terminus cause it to become 
desensitized to external stimuli, and this also leads to β-arrestin recruitment and receptor 
internalization.61 However, it should be mentioned that morphine does not cause receptor 
phosphorylation at high levels.61 Rather, endogenous ligands such as etorphine are responsible for such 
effects.55
1.2.3 Opioid Addiction and Its Effects on HIV/AIDS Infected Individuals
While opiates are effective at reducing pain, they increase the risk of drug-based addiction and 
abuse in individual patients.56–59 This abuse is particularly dangerous in patients that are infected with 
HIV, as it has been shown that the rate of HIV-1 progression spikes in opiate-addicted patients with 
AIDS.62–68 This HIV-1 progression coupled with opiate addiction increases the likelihood of HIV-
associated neurocognitive disorders (HANDs) and neurological complications of AIDS (neuroAIDS).62, 
66 Thus, the use of opiates by HIV-infected patients appears to have a complimentary effect on the rate 
of viral proliferation.65–67 
Studies have shown that MOR is responsible for the addictive properties of morphine.58, 59 In 
MOR-knockout mice, morphine's addictive properties were abolished.58 Also, MOR-knockout mice are 
less prone to develop addictions to other drugs such as nicotine and alcohol, indicating the importance 
of the MOR in influencing general addiction.58, 59 However, despite their involvement in producing and 
prolonging addiction, MOR agonists such as morphine are still used to treat pain.  In fact, many novel 
drugs used to treat pain are modified analogs of morphine.60 As such, most of the new drug-design 
projects involving opiates focus not only on improving the selectivity and potency of MOR agonists, 
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but also making them less addictive.  Opiate addiction is still a problem in general society, however, in 
particular among HIV patients.62–68 
1.2.4 Addiction in NeuroAIDS
In HIV-infected patients, the progression of AIDS is accelerated by the use of opiates.69–71 The 
central nervous system (CNS) in particular seems to be the most affected region of AIDS progression in 
opiate-addicted individuals.72, 73 This is because of the fact that both CCR5 and MOR are expressed on 
the glial cells (astroglia and microglia) of the CNS and MOR can heterodimerize with CCR5 when 
activated by an opiate.69–71 In fact, MOR has been shown to effect immunomodulation by acting as a 
chemokine and potentiating the downstream signaling pathways of chemokine receptors.74, 75 Also, 
activation of MOR has been shown to increase the expression levels of CCR5, resulting in more co-
receptors for HIV.76, 77
HIV does not directly degrade neurons of the CNS, but instead infects the microglia and 
astroglia surrounding them.73, 76 This is because CCR5 is more prevalent on glial cells than on 
neurons.76 When HIV-1 infects glial cells, it not only destroys such cells when new virions are released 
into the external environment; it also releases byproducts, such as viral proteins and chemokines, that 
result in degeneration of neuronal cells.76 The proximity of glial cells to neurons result in the excreted 
toxins damaging neurons, which leads to inflammation.76, 77 Opiates potentiate the infection of HIV in 
microglia through MOR dimerizing with CCR5, which makes the latter protein more susceptible to 
HIV-1 attachment.69–71 
1.2.5 Mu Opioid Receptor Ligands: Agonists and Antagonists.
There are both known exogenous and endogenous agonists that bind to MOR.78, 79  While the 
former are small molecules derived from morphine (5), the latter are peptides.78 Because of morphine's 
12
unwanted side-effects, the development of new MOR agonists that have reduced addictive potentials 
has been explored.79 The table below shows some of the peptidic and non-peptidic agonists of MOR. 
One of the peptidic agonists, DAMGO (7), is a synthetic peptide based off of an enkephalin, and it is 
highly selective for MOR over the other opioid receptors.78
Table 2. Three MOR agonists.  
Name Structure KOR Ki 
(nM)
DOR Ki 
(nM)
MOR Ki 
(nM)
Morphine
O
HO
H
N
OH
5
33.7 111 2.70
Fentanyl
N
O
N
6
387 403 1.50
DAMGO
HO
O
N
H
H
N
O
O
N
HN
OH
NH2
O
7
534 634 1.23
Along with the agonists, there have been several antagonists developed to treat morphine and 
general opiate addiction (N.B., see table below).80–83 These, like the agonists, also include both small 
molecules and synthetic peptides.80–83 Both naloxone (8) and naltrexone (9) are non-selective 
antagonists for all three traditional opioid receptors (i.e., DOR, KOR and MOR).80
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Table 3. Six MOR antagonists.  
Name Structure KOR Ki (nM) DOR Ki (nM) MOR Ki (nM)
Naloxone
O
OH
N
HO O
8
1.95 49.0 0.62
Naltrexone
O
OH
N
HO O
9
0.28 6.94 0.11
β-FNA
O
OH
N
HO HN
O
O
O
10
3.40 78.7 1.10
Clocinnamox
O
H
N
N
HO
Cl
O
O
11
5.70 1.90 0.70
Cyprodime OMe
N
OO
12
2180 245 5.40
14
CTAP
D Phe Cys Tyr D
Trp
ArgThrPenThrH2N
13
5310 8450 2.10
To improve selectivity for MOR over the other two opioid receptors, β-FNA (10) was 
synthesized.83 While β-FNA binds to all three receptors, it only binds to MOR irreversibly.83 Notice, 
however, that the only difference between β-FNA and naltrexone is the group attached to the C-ring of 
the morphanin core.  This fact supports the “message-address” concept proposed by Portoghese et al.84 
This concept is based on the premise that the morphanin scaffold has two main parts: 1) the morphanin 
core, or the “address” portion of the molecule, that is active at all opioid receptors and 2) the “message” 
portion of the molecule, which is located off of the C-ring and helps determine receptor selectivity for 
the molecule. In other words, selectivity for a particular receptor can be altered merely by changing the 
group (i.e., the “message” portion) attached to the C-ring of a morphine-derived molecule.  This is why 
β-FNA is selective for MOR whereas naltrexone is not despite having similar core structures.83, 84 The 
molecule clocinnamox (11) was also designed using the message-address concept in order to improve 
selectivity for MOR over the other two traditional opioid receptors.81 Cyprodime (12) has the highest 
selectivity for MOR among the molecules presented here.80 This is because removing the dihydrofuran 
ring from a morphanin core reduces its affinities for KOR and DOR but not MOR.80 Finally, CTAP 
(13), a cyclic peptide, has the greatest affinity for the MOR receptor among the molecules listed in the 
table with a Ki in the low nanomolar range.82
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Figure 4.  β-FNA (10) illustrates the message-address concept for opioid receptor selectivity.  
1.3 GPCR Dimerization
It was thought that all GPCRs acted in a monomeric fashion in which the protein's activation 
was dependent only upon the binding of a single ligand.  However, evidence was discovered indicating 
that GPCRs could dimerize with one another and sometimes form oligomeric complexes.85, 86 It was 
also discovered that the binding of one ligand to a GPCR could prevent another GPCR from interacting 
with its ligand.85 This interaction, termed “cross-talk,” illustrates the ability of an activated GPCR to 
affect the activity of another GPCR for a ligand through dimerization.85, 86 Furthermore, it has been 
demonstrated that receptor cross-talk can either enhance or decrease the activity of an adjacent, 
dimerized receptor for its ligand.85–89
Advanced techniques have been developed for detecting the dimerization of two GPCRs, 
including bioluminescence resonance energy transfer (BRET), fluorescence resonance energy transfer 
(FRET), and advanced crystallization techniques.91–95 For FRET, two proteins are tagged with two 
different fluorescent proteins.91, 95 If the proteins dimerize, then when one of the proteins (i.e., the donor 
chromophore) is stimulated by fluorescent light it will transfer energy of a particular excitation 
wavelength to the adjacent protein (i.e., the acceptor chromophore), causing it to also emit light of a 
particular wavelength.91, 95 It is important to note that the acceptor chromophore will only emit light if 
the donor chromophore has dimerized with it.  BRET also uses a similar technique, except the donor 
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chromophore is coupled with a bioluminescent luciferase enzyme and therefore doesn't need to be 
stimulated by light from an external source.91, 95 Either way, both techniques are ideal for detecting the 
presence of protein dimers using fluorescent light.91, 95 A more modern technique using GPCR 
crystallization coupled with atomic-force microscopy is also a good way of detecting GPCR 
dimerization.92
It is important to mention that GPCR dimerization has an important function on receptor 
activity and signaling.  As mentioned beforehand, GPCR dimerization can either enhance the affinity of 
a receptor for its ligand or decrease a receptor's affinity for its ligand.  The former scenario, termed 
positive cooperativity, leads to a receptor with greater signaling and function, whereas the latter 
situation, termed negative cooperativity, leads to a receptor with decreased signaling capabilities.86
Figure 5.  Positive and negative cooperativity in GPCR dimerization.  
1.3.1 Mu Opioid Receptor Dimerization
There have been multiple studies illustrating the ability of MOR to dimerize with another MOR 
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and other GPCR types.96–99 MOR has been shown to dimerize with KOR, DOR, NOR, CCR5 and 
cannabinoid receptors.96–100 Interestingly, when MOR is dimerized with another receptor, it is able to 
activate signaling pathways that it cannot activate on its own.99 For example, when not dimerized with 
another opioid receptor, neither MOR nor DOR can couple with the Gαq/11 G protein.99 However, when 
coupled together, the MOR-DOR complex activates the Gαq/11 signaling pathway quite readily.99 This 
suggests that certain heterodimers can activate signal pathways that the monomers cannot activate 
themselves.  Dimerization may also enhance or inhibit the rate of receptor desensitization and 
internalization, as evidenced by studies involving the MOR-NOR heterodimer.101
1.3.2 Bivalent Ligands Targeting GPCR Heterodimers.
Bivalent compounds are necessary probes for studying the interaction between two distinct 
monomers that form a dimer.102–104 Bivalent compounds are molecules that contain two distinct 
pharmacophores, and they can either be classified as homobivalent or heterobivalent depending on 
whether or not they contain the same or different pharmacophores.102 In studies involving the 
dimerization of the same two protein types (homodimerization), a homobivalent molecule is necessary 
to analyze the interaction; the converse is true for studies involving the dimerization of two dissimilar 
protein types (heterodimerization).103 By targeting a dimer of GPCRs using a bivalent compound, new 
pharmacological profiles can be obtained revealing information particular to that dimer.102, 104 Also, 
bivalent compounds can lead to higher affinity and higher selectivity for the target in question.102–104 
The two pharmacophores in a bivalent compound are often attached to each other – or bridged – 
by a linker of carbon atoms.102–104 This linker both allows each pharmacophore to interact with its 
receptor individually and also enables both pharmacophores to bind at a similar time.  Researchers have 
anticipated that the average distance between two GPCR dimers in anywhere from 27 Å to 32 Å. 
Therefore, a linker should be somewhere within that range.103
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There are numerous linkers targeting MOR heterodimers that have been synthesized to date.105-
108  They include an MOR agonist, oxymorphone, and a type 2 cholecystokine (CCK2) receptor 
antagonist being synthesized across a linker in order to determine if the MOR and CCK2 associate in  
vivo (14).105  They also include compound 15, a MOR-KOR binding compound that contained the 
MOR antagonist naltrexone and the KOR antagonist 5'-GNTI.106
Table 4. Selective bivalent compounds targeting MOR and another receptor.
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Finally, there was a series of compounds similar to 16 that contained both pharmacophores for 
DOR and MOR.107 This series was made to assess the functional role of the MOR-DOR heterodimer in 
analgesia.107 Portoghese et al. wanted to see whether or not a bivalent analgesic compound could be 
designed that mitigated the deleterious, addictive side-effects of morphine.107 16 was comprised of an 
MOR agonist, oxymorphone, and a selective DOR antagonist, naltridole.  The two pharmacophores 
were separated by a 21-atom spacer with a maximum length of 25.4 Å.  It was found that this molecule 
was 50-fold more potent than morphine without producing tolerance or dependence side-effects, which 
also illustrated the importance of DOR in potentiating the activity of MOR.107
However, because molecule 16 was not selective for the MOR-DOR heterodimer over the 
MOR-MOR and DOR-DOR homodimers, Harvey et al. developed two fined-tuned MOR-DOR 
bivalent compounds – 17 and 18 – a  that were very selective for their intended target.108 The reason 
they did this was because 16 could also interact with the MOR-MOR and DOR-DOR homodimers with 
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similar affinity to the MOR-DOR heterodimer.108 In order to solve this problem and fine-tune their 
molecule, they constructed 17, a molecule containing the MOR agonist oxymorphone and a low 
affinity DOR antagonist, ENTI, and 18, a molecule containing the MOR antagonist naltrexone and a 
low affinity DOR agonist, DMSNC80.  These molecules had reduced affinity for the DOR-DOR and 
MOR-MOR homodimers.108 Of note, both compounds synergistically raised the binding affinity for the 
DOR pharmacophore when the binding assays were conducted using membranes composed of MOR-
DOR relative to assays conducted using DOR alone membranes.108 The concept of fine-tuning the 
ability of bivalent ligands to bind to a particular dimer using high and low affinity pharmacophores is 
an important aspect of drug design using bivalent compounds.
2.  Bivalent Ligands Targeting the Putative CCR5-MOR Heterodimer
2.1  Project Design
The effects of human immunodeficiency virus (HIV)-1 has been shown to be potentiated by the 
abuse of various drugs, including alcohol, opioids and cocaine.62, 64-67 In fact, many cases of HIV 
infection can be attributed to the use of contaminated needles.109 The abuse of certain drugs – opioids in 
particular – has been associated with the mu opioid receptor (MOR) due to the ability of those drugs to 
bind to and agonize MOR.  Furthermore, the  binding of opioids to MOR have been shown to change 
the normal response of the immune system, a condition called immunomodulation, due to the ability of 
MOR to regulate chemokine receptors; this condition, in turn, has been shown to produce negative 
immunological effects due to the inability of modulated chemokine receptors to respond to infections.62, 
110 Given that HIV progression is associated with the immune system and the functioning of 
lymphocytes, changes in the immune system can result in the potentiation of HIV.62, 68
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Chemokine receptor CCR5, a G-protein coupled receptor (GPCR), is expressed on many cell 
types, including lymphocytes and neuronal cells.32, 33, 111, 112 CCR5 has been shown to act as a co-receptor 
in HIV cellular invasion.  It has also been demonstrated that the inhibition of CCR5 mitigates HIV viral 
entry into lymphatic cells and cells of the central nervous system (CNS).111-113 Maraviroc, a synthetic 
CCR5 antagonist, was developed by Pfizer to combat the invasion of HIV into lymphatic cells in the 
mid 2000's.113 In combination with different antiretroviral therapies, maraviroc has been shown to 
inhibit the progression of HIV-1 infection.  However, other health complications, such as HIV-
associated neurocognitive disorders (HANDS), effect half of AIDS patients and are not mitigated by 
maraviroc.114, 115 These patients are characterized by behavioral abnormalities such as reduced cognition 
and motor control, health effects resulting from the invasion of HIV into cells of the CNS, in particular 
microglia and astrocytes.114, 115 Since microglia defends primary neuronal cells from infection and 
astrocytes are responsible for the delivery of nutrients into the brain, complications can result from the 
destruction or induced inactivity of these cell types.76 The immunocompromised state of these cells by 
HIV-1 infection results in a condition known as neuroAIDS.114, 115
The increased risk of HIV-1 infection in cells of the CNS has been linked to the stimulation of 
MOR by opiates.62, 64–66, 75, 77 This is because, once agonized by an opioid, MOR may produce synergistic 
interactions with CCR5.75, 77 An example of this is how activation of MOR by opioids up-regulates the 
expression of CCR5 in cells, which in turn promotes HIV-1 infection via the virus using CCR5 for viral 
entry.77 Opiates can also indirectly damage primary neuronal cells by causing inflammation in microglia 
and astrocytes.63, 116 The type and extent of neuronal injury to different neurons by HIV-1 infection has 
also been correlated with the amount of MOR expressed on those neuronal cell types.116, 117
Verification of the synergism between the MOR and CCR5 has been demonstrated by the ability 
of the receptors to heterodimerize and undergo receptor crosstalk.118, 119 Since this crosstalk was 
discovered to take place in lymphocytes, it has been hypothesized that it also takes place in neurons and 
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therefore may lead to the progression of neuroAIDS.118 Recently, a bivalent compound (18) was 
synthesized that contained maraviroc, a CCR5 antagonist, and naltrexone (N.B., converted to 6β-
naltrexamine), an MOR antagonist, each separated by a linker (Figure 6).120 The purpose of this 
bivalent compound was to study the pharmacological profile of CCR5-MOR heterodimerization and its 
relationship with neuroAIDS.120  It is worthy to note that this bivalent compound is the first compound 
to target the putative MOR-CCR5 heterodimer and is therefore considered a novel chemical probe in 
the study of neuroAIDS and HANDS.120
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Figure 6.  The first reported bivalent compound targeting the CCR5-MOR heterodimer.24
The purpose of synthesizing the bivalent compound (18) was to design a molecule that could 
antagonize both the MOR and CCR5 receptors simultaneously, as shown in Figure 7.  Both maraviroc 
and naltrexone were selected based on their binding affinities for CCR5 and MOR (respectively) and 
their pharmacological profiles.120 It should be noted that both molecules had to be functionalized with 
an amino group in order to initiate linker attachment via amide coupling.120 The structure of the linker 
and its attachment to maraviroc and 6β-naltrexamine were based on the work of Daniels et al. with 
various opioid receptors and their antagonists.107 In their research, they found that using a 21-atom 
spacer was optimal in studies involving opioid receptor heterodimerization, and therefore 18 was 
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synthesized in the study of CCR5-MOR heterodimerization carried the same spacer length.107, 120
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Figure 7.  Strategy for designing a bivalent compound to target the CCR5-MOR heterodimer.
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From molecular modeling studies involving the docking of maraviroc to a homology model of 
receptor CCR5, it was hypothesized that the phenyl ring could accommodate either a 3- or 4-position 
linker (Figure 8).121 Therefore, testing a bivalent compound involving a 3-position linker was necessary 
to determine whether or not such a compound could produce better activity at the CCR5 receptor 
relative to the original 4-position compound (18).
Figure 8.  Maraviroc bound to a homology model of receptor CCR5.121 
After 18 was synthesized and tested in biological assays, another novel bivalent compound (19) 
utilizing maraviroc and 6β-naltrexamine pharmacophores was also synthesized and tested in biological 
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assays, only this time the amine group was altered from the 4-position to the 3-position of maraviroc 
(Figure 9).  This was done to allow for fine-tuning of the bivalent compound to the CCR5-MOR 
heterodimer (i.e., to determine which linker attachment produced better binding). 
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MOR IC50: 17.1 ± 4.9 nM 
CCR5 IC50: 1340.0 ± 110.0 nM
Figure 9.  Comparison of the abilities of 18 and 19 to target MOR and CCR5.
By using calcium mobilization assays to determine the functionality of each bivalent compound 
(18 & 19) to the MOR-CCR5 heterodimer, it was concluded that the modification of the amine to the 3-
position produced a less potent bivalent compound.  Whereas both 18 and 19 retained their antagonism 
toward MOR (IC50's of 29.9 ± 2.4 and 17.4 ± 5.7, respectively), neither 18 nor 19 produced effective 
binding to CCR5 (IC50's of 6240 ± 250 and 14040 ± 350, respectively).  Overall, there was a 350-fold 
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decrease in activity for 18 but a 700-fold decrease in activity for 19.  Moreover, in CCR5 and MOR 
radiobinding assays, compound 19 completely lost its affinity to the CCR5 receptor.
After determining the efficacy of the 4-position over the 3-position, further fine-tuning of the 
bivalent compound was conducted to increase binding to the CCR5-MOR heterodimer.  The 21-atom 
spacer in 18 was changed to a 19-atom spacer and a 23-atom spacer in 20 and 21, respectively (Figure 
10).  This was done because the in silico research conducted by Daniels et al. was inconclusive 
regarding the spacer's length.107 
Controls to demonstrate MOR-binding (22 and 23) and CCR5-binding (24 and 25) were also 
synthesized (Figure 10).  Dr. Yunyun Yuan synthesized the bivalent compounds and CCR5-binding 
controls (20, 21, 24, 25), whereas Thomas Raborg synthesized the MOR-binding controls (22 and 23). 
In this way we set out to test the relative potency of each novel bivalent compound to the original 
bivalent compound containing the 21-atom spacer (18).  
27
ONHO
OH
N
H
O
N
H
O
N
H
O
O
O
N
H
N N
N
N
HN H
O
F
F
n
20, n = 3
21, n = 7
O
NHO
OH
N
H
O
O
N
H
O
N
H
O
O
O
N
Hn
N
H
O
O
O
N
H
N N
N
N
HN H
O
F
F
N
H
O
O
O
N
H n
24, n = 3
25, n = 7
22, n = 3
23, n = 7
Figure 10. Compounds synthesized to target CCR5, MOR and the CCR5-MOR heterodimer.
2.2 6β-Naltrexamine Synthesis
In order to hook up the monoprotected 5- and 9-carbon linkers with naltrexamine through an 
amide coupling reaction, the opioid naltrexone, a potent µ-opioid receptor antagonist, would have to be 
converted to 6β-naltrexamine (38).  38 was already synthesized according to the synthetic route 
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illustrated in scheme 2 by the Portoghese group.124
  
This two-step synthetic route first converted 
naltrexone to a 6β-naltrexamine derivative containing two benzyl groups attached to a tertiary amine, 
replacing the keto group at the six position.124 Then, this dibenzylamine derivative was reduced using 
Pd/C hydrogenation to form 6β-naltrexamine.124
O
OH
N
HO O
1) PhCOOH, EtOH, .5h
2) PhCOOH, TsOH, NHBn2 
     toluene, reflux
3) EtOH, NaCNBH3, MS
O
OH
N
HO NBn2
36 37
O
OH
N
HO NH2
38
10% Pd/C, H2
MeOH, HCl
Scheme 1. 6β-naltrexamine (38) synthesis.
The first time the reductive amination reaction was attempted, 1.00 g naltrexone (36) was added 
to 75 mL absolute EtOH and 175 mL anhydrous toluene, making a very dilute solution.  The reaction 
was kept under anhydrous conditions and placed under a Dean-Stark trap, whereby any water formed 
from the reaction would be extracted from it (the solvent collected in the Dean-Stark trap was 
discarded).  Additionally, molecular sieves were added to further prevent the presence of water from 
interfering with the second step of the reaction.  After the dibenzylamine was added, the reaction was 
allowed to reflux for one night.
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In the morning, the solvent mixture was found to have evaporated, leaving a burnt residue at the 
bottom of the flask.  One hundred and fifty milliliters of toluene was added to the reaction with [1.1] 
equivalent NaBH3CN, but, even after two days, 37 did not form (verified by TLC, 9:1:0.01, DCM: 
MeOH:NH4OH).  The reaction would have to be re-attempted, as the dibenzylamine derivative would 
not form.
The second time the reductive amination reaction was attempted, 0.50 g naltrexone was added 
to 75 ml absolute EtOH and 175 mL anhydrous toluene, making a more dilute solution than the 
previous attempt.  The reaction was still kept under anhydrous conditions and placed under a Dean-
Stark trap.  [1.2] equivalent dibenzylamine was also added  However, this time, 150 mL toluene and 50 
mL EtOH were added at the end of the day to ensure that the solvent mixture did not fully evaporate.
In the morning, [1.1] equivalent NaBH3CN was added to the reaction mixture.  After two days 
the product was confirmed to have formed by TLC (9:1:0.01, DCM: MeOH:NH4OH).  The crude 
product was filtered and concentrated in a flask, and then the product (37) was recrystallized by 9:1 
MeOH:H2O.  The reaction yielded 0.250 g product at 34% yield.  This is approximately twice as less as 
the yield reported by the Portoghese group.124
  
 It was speculated that this was because of the small 
amount of starting material (37) used in the reaction (by contrast, the Portoghese group used about 2.00 
g naltrexone).
The 6β-naltrexamine intermediate 37 was then subjected to deprotection using Pd/C 
hydrogenation.  0.250 g 37 was put in a H2
 
flask with 10% Pd/C and HCl and placed under H2 gas at 60 
psi.  10% Pd/C was added two more times over the course of three days, as the product (38) was having 
trouble forming.  For example, after the third 10% equivalent was added, TLC (9:1:0.01, 
DCM:MeOH:NH4OH) revealed three separate spots, the starting material (37), an intermediate and the 
product (38).  The reaction mixture was filtered a day after the third 10% Pd/C addition and 
recrystallization (9:1, diethyl ether:MeOH) was attempted, but no crystals formed.  The precipitate was 
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a crude, orange, sticky product with multiple spots on the TLC.  It was determined that the reductive 
amination reaction would have to be reattempted, this time ensuring that the product (37) was pure 
enough so that crystals of 38 would form at the end of the second reaction.
A third reductive amination reaction was attempted, this time with 0.50 g naltrexone (36) added 
to 75 mL absolute EtOH and 150 mL toluene.  The reaction was again placed under a Dean-Stark trap 
with molecular sieves, and [1.2] equivalent dibenzylamine was added.  Like in the second attempt, 150 
mL toluene and 50 mL EtOH were added to the reaction mixture at the end of the day to ensure that the 
solvent would not totally evaporate.  On the second day, [1.1] equivalent NaBH3CN was added to the 
reaction.  When the product (37) formed, the reaction was filtered and concentrated to dryness.  The 
crude product was again recrystallized in 9:1 MeOH:H2O.  No product was left behind in the mother 
liquor, so the solid precipitate was dissolved in DCM and further purified using column 
chromatography (20:1:0.01, DCM:MeOH:NH4OH) to give 0.260 g 37 at a yield of 35%.  This is 
approximately twice as less as that reported by the Portoghese group.124
  
Reasons for this might include 
both the amount of SM that was used in the reaction and the dual purification process (i.e., by 
recrystallization and purification of the crude recrystallized product).
 0.260 g 37 was then placed in a H2
 
flask with 10% Pd/C and HCl under H2 gas at 60 psi.  10% 
Pd/C was added two more times within a period of four days to ensure that the reaction would go to 
completion.  The reaction was monitored by TLC (9:1:0.01, DCM:MeOH:NH4OH) until completion, 
and then it was filtered through celite and concentrated to dryness.  The resultant crude produce was 
recrystallized in 9:1 diethyl ether:MeOH.  However, unlike the first time recrystallization using this 
ratio was attempted, the product that precipitated out of the solvent was white and powdery.  0.199 g 38 
was extracted at a yield of 96%.
2.3  Synthesis of the monovalent µ-Opioid control compounds
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2.3.1  Monoprotection of diamines
The monovalent µ-opioid control compound was previously synthesized using the synthetic 
route illustrated in scheme 1.120  However, unlike the previous synthesis, which used 1,7-
diaminoheptane as the starting material, the number of carbon atoms in the diamine were changed from 
seven to five and nine (i.e., 1,5-diaminopentane (26) and 1,9-diaminononane (27), respectively) for the 
current experiment.  The compounds were synthesized in tandem using similar reaction conditions and 
reagents.
H2N NH2(  )n
Cbz-Cl
DCM/MeOH
    0 - 5 oC26, n = 3 
27, n = 7
H2N NHCbz(  )n
28, n = 3
29, n = 7
Scheme 2. Monoprotection of diamines.
First, diaminopentane (26) and diaminononane (27) were monoprotected using a carboxybenzyl 
group according to various reported methods.120, 122, 123 The first time this reaction was tried, 1 g of 
starting material was added to 300 mL DCM and 300 mL MeOH, making a very dilute solution.  The 
solution was further diluted by adding [1] equivalent benzyl chloroformate that was dissolved in 200 
mL MeOH dropwise over the course of one week at room temperature.  After the reaction was 
completed, TLC (9:1:0.01 DCM, MeOH, NH4OH) was taken to reveal that the majority spot (UV and 
iodine active) was that of the starting material.  Some diprotected product formed, but very little 
monoprotected product formed.  The difficulties of the reaction were further compounded by the fact 
that there were numerous byproducts in the reaction mixture that made purification difficult.  Yields 
from this reaction under these conditions and parameters were 5-8%.
The work-up and purification of the monoprotected product is worthy of note, as many steps 
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were taken to ensure that the product was pure enough to initiate the next step in the reaction scheme. 
Special emphasis was put on purifying the product in this reaction because, as the first step in the 
synthetic route, an impure product would make all following reactions more difficult to initiate and 
purify.  The difficulties of working with impure starting material were noted even as early as the second 
reaction (i.e., the one utilizing diglycolic anhydride in scheme 1), as, the first time it was tried, it was 
impossible to recrystallize the product given the impurities mixed with the starting material.
When the crude product had been concentrated to dryness, it was dissolved in DCM and put in a 
separation funnel.  Then, H2O – which is immiscible with DCM – was put in the separation funnel and 
its pH was reduced to 1 using 38% HCl.  The purpose of making the water acidic was to ionize the 
unprotected diamine and monoprotected diamine and thus make them much more polar than the 
diprotected byproduct.  It was theorized that, because the diprotected byproduct contained no primary 
amines, it would be much harder to ionize than either the unprotected diamine or the monoprotected 
diamine, and thus it would remain in the denser, non-polar DCM layer while the other two compounds 
became more miscible in water.  Once the DCM layer was drained from the separation funnel, the 
remaining water layer had its pH increased to 12 ~ 14.  This was done in order to make the 
monoprotected product less soluble in water and more soluble in DCM.  In this way the monoprotected 
product was separated from the more polar starting material.  Results of the chemical separation were 
confirmed with TLC (9:1:0.01 DCM:MeOH:NH4OH).
Once the DCM containing the monoprotected compound was concentrated, it was redissolved 
in 1 mL DCM in preparation for column chromatography.  Although the monoprotected product had 
been separated from its diprotected byproduct and unprotected starting material, there were still other 
impurities and byproducts that had formed in the reaction.  Many of these had similar Rf values with 
the monoprotected product on TLC.  The column was done in gradients, starting from 50:1:0.01 
DCM:MeOH:NH4OH and becoming progressively more polar.  The 1,5-monoprotected diamine was 
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quite difficult to purify, as it didn't begin to elute from the column until the ratio was reduced to 5:1 
DCM:MeOH.  The 1,9-monoprotected diamine was easier to purify, as it was larger and less polar and 
therefore eluted from the column at the much higher ration of 10:1 DCM:MeOH.  Regardless, both 
compounds required another round of column chromatography to separate the monoprotected product 
from other byproducts, as there were still impurities with the product in both cases.
The next time the reaction was tried, similar previously reported methods were utilized, but this 
time the amount of benzyl chloroformate was modified.  Instead of adding [1] equivalent of benzyl 
chloroformate, [1.5] equivalent was added in the hope that it would drive the reaction to completion, 
thus forming more monoprotected product.   This was done due to the large amount of starting material 
that remained unreacted the first time the reaction was tried.  It was hypothesized that adding more 
equivalents of benzyl chloroformate would reduce the amount of starting material in favor of more 
monoprotected product.  Even though doing so would increase the amount of diprotected byproducts as 
well, since there was far more starting material left over after the reaction the first time it was tried, this 
result was considered negligible.  One gram of the starting material was diluted in 300 mL DCM and 
300 mL MeOH, making a very dilute solution, and the [1.5] equivalent benzyl chloroformate was 
added with 200 mL MeOH dropwise over the course of one week.  After the reaction was completed, 
TLC (9:1:0.01 DCM, MeOH, NH4OH) was taken to reveal two dark spots (UV and iodine active) – 
assumed to be the monoprotected product and diprotected byproduct – above the spot containing the 
starting material.  As in the previous reaction, however, many byproducts were revealed to be around 
the monoprotected product.  This made purification difficult, and the yields from this reaction under 
these conditions were also very low (approximately 10-15%).
From both of the previous methods, the first using [1] equivalent benzyl chloroformate and the 
latter using [1.5] equivalent benzyl chloroformate, two problems still persisted with the reaction: (1) the 
low yield of monoprotected product and (2) the formation of numerous byproducts which made 
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purification difficult.  The methods previously detailing the reaction, however, suggested modifying the 
temperature under which the reaction proceeded in order to decrease the amount of byproducts formed 
and increase total product yield.122, 123 According to the literature, decreasing the temperature of the 
reaction from room temperature to 5 – 10 oC would result in less diprotected byproduct and less 
byproducts similar in size and polarity to the monovalent product, thus making purification much less 
difficult and time-consuming.122, 123 
The next time the reaction was proceeded by adding 1 g of starting material diluted in 300 mL 
DCM and 300 mL MeOH.  However, instead of leaving the reaction at room temperature, the 
temperature was lowered to 0 – 10 oC and maintained over the course of one week as [1.5] equivalent 
benzyl chloroformate was added dropwise.  After the reaction was completed, TLC (9:1:0.01 DCM, 
MeOH, NH4OH) revealed some starting material left (UV and iodine active), but mostly diprotected 
byproduct and monoprotected product.  It is interesting to note, however, that some of the byproducts 
which had previously appeared on the TLC plate were absent.  Because of the absence of these 
byproducts, purification was easier, but it was still quite low, at approximately 10 – 20% yield for both 
monoprotected products (28 & 29).
Despite the minor improvements in yield from the first reaction, there were still drawbacks to 
the reaction that persisted.  It seemed that regardless of the amount of benzyl chloroformate used and 
regardless of the temperature, there were still going to be numerous byproducts formed, and the 
diprotected byproduct would always predominate over the monovalent product.  Furthermore, the yield 
was still quite low, and it seemed like the reaction would have to be repeated numerous times in order 
to gather enough product to go onto the next step in the synthetic scheme.  In order to improve the yield 
of the reaction and limit the amount of byproducts formed, it was suggested that the reaction  be placed 
above a Dewar flask containing acetone and dry ice, cooling the temperature to -10 – 0 oC, thus making 
the reaction conditions even cooler than attempted previously.  Furthermore, using dry ice in acetone 
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would make the reduced temperature easier to maintain.  It was also suggested that the equivalent of 
benzyl chloroformate be modified to [.5] equivalent in order to reduce the chances of byproduct 
formation, in particular the diprotected byproduct.  Furthermore, because of the cooler temperatures 
and smaller equivalent of benzyl chloroformate, less solvent would be needed to conduct the reaction. 
In conclusion, two conditions would be changed for the next reaction: the temperature and equivalent 
of benzyl chloroformate.  These modified parameters would decrease the amount of solvent required 
for the reaction to work.
As before, 1 g of the starting material was placed in a flask.  This time, however, only 250 mL 
DCM was used as a solvent.  The reaction temperature was reduced to -10 – 0 oC using acetone and dry 
ice, and [.5] equivalent benzyl chloroformate in 50 mL DCM was added dropwise over the course of 
one day.  The temperature was monitored and dry ice and acetone were continuously added in order to 
maintain a constant low temperature.  After the reaction was complete, TLC (9:1:0.01 DCM, MeOH, 
NH4OH) revealed little-to-no starting material, no diprotected byproduct and very little additional 
byproducts around the monoprotected product (UV and iodine active).  The largest spot was the 
monoprotected product.  The reaction was concentrated and purified using column chromatography 
(5:1:0.01 DCM, MeOH, NH4OH for the monoprotected diaminopentane and 9:1:0.01 DCM, MeOH, 
NH4OH for the monoprotected diaminononane).  0.770 g (28) was collected at a yield of 33%, by far 
the greatest for the reaction involving 1,5-diaminopentane starting material. 0.444 g (29) was collected 
at a yield of 24%, also the greatest for the reaction involving 1,9-diaminononane starting material.  The 
compounds were verified by 1H NMR. 
2.3.2  Monoprotected Diamines Reacting with Dyglycolic Anhydride
The next step in the reaction scheme consisted of using 28 or 29 as the starting material and 
converting it to a carboxylic acid by coupling its unprotected primary amino group with diglycolic 
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anhydride.  This reaction required an exact measurement of the amount of starting material, as reacting 
it with any more or less than [1] equivalent diglycolic anhydride resulted in a reaction mixture that was 
difficult to purify by recrystallization (N.B., the carboxylic acid product could not be separated from 
the reaction mixture by column chromatography, given the polarity of the compound).  The first time 
the reaction was attempted, about 0.100 g of 28 was put inside a flask with 3 mL THF and the reaction 
temperature was reduced to 0 – 5 oC using an ice-water bath.  Then, [1] equivalent diglycolic anhydride 
was added and the ice-water bath was removed, thus allowing the reaction to reach room temperature. 
After one day, the reaction was concentrated and recrystallization in diethyl ether:MeOH (9:0.01) was 
attempted.  The solvent ratios were varied, but the product did not form.  Given that the reported yield 
for this reaction was over 90%, it was assumed that the starting material was not weighed accurately, 
and this was why the product did not recrystallize out of the solution.
H2N NHCbz(  )n
28, n = 3 
29, n = 7
O
O
O
O
THF, RT NH
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30, n = 3
31, n = 7
Scheme 3. Cbz-protected diamines reacting with diglycolic anhydride.
The second time the reaction was tried, the starting material was dried using a vacuum pump in 
a small 100 mL flask in order to increase the accuracy of the measured weight.  After this, the starting 
material was put in a flask with THF and the temperature was again reduced to 0 – 5 oC using an ice-
water bath.  [1] equivalent diglycolic anhydride was added and the ice-water bath was removed, 
allowing the reaction to reach room temperature.  A day later, the reaction was concentrated and 
recrystallization was attempted using diethyl ether:MeOH (9:0.01).  This time the product was able to 
recrystallize out of the reaction mixture after one day of stirring in the diethyl ether:MeOH solvent 
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mixture.  About 0.270 g 30 was obtained at a yield of 30% and 0.170 g 31 was obtained at a yield of 
also 30%.  While adequate for conducting the remaining reactions in the synthetic scheme, these yields 
were much lower than yield reported in the literature.120
2.3.3  Monoprotected Intermediates Undergo Amide-Coupling Reaction with 6β-naltrexamine
Compounds 30 and 31 were then attached to 6β-naltrexamine (see scheme 2 for synthetic route 
of 6β-naltrexamine) via an amide coupling reaction.  The reaction consisted of putting the acid linker 
(30 or 31) in 1 mL anhydrous DMF, forming a concentrated 1 M solution.  This solution was allowed to 
stir overnight with molecular sieves under N2 gas protection in order to ensure anhydrous conditions. 
This stage of the reaction was critical, as water would impede the formation of the acid-EDCI 
intermediate, which was required for the coupling reaction to occur in a timely manner.  The following 
day, [1.5] equivalent HOBt and [1.5] equivalent EDCI catalysts were added to the reaction according to 
reported methods.120  Then, [1] equivalent 6β-naltrexamine in 1 mL anhydrous DMF was added 
dropwise for the coupling reaction to proceed.  The reaction was given a few days to go to completion 
and TLC (9:1:0.01 DCM:MeOH:NH4OH) was taken to ensure that the 6β-naltrexamine starting 
material was consumed.  For the formation of the 6β-naltrexamine with the 1,9-monoprotected acid 
control, an additional [.5] equivalent of EDCI was added to the reaction in order for the starting 
material to be consumed.  Once the starting material was consumed, the reaction was filtered through 
celite and concentrated to dryness.  The crude product was recrystallized in 20:1:0.01 
DCM:MeOH:NH4OH column chromatography.  0.165 g 32 was obtained at a yield of 60%, and 0.170 
g 33 was obtained at a yield of 43%.  These results mimic the yield reported in the literature.120
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Scheme 4. Amide-coupling reaction involving the protected diamine and 6β-naltrexamine.
2.3.4  Deprotection
Compounds 32 and 33 were then subjected to deprotection.  For this reaction, the starting 
material was placed inside a H2 flask with MeOH and 10% Pd/C.  The reaction took about three days 
for both starting materials.  Over the course of the reaction time, multiple 10% Pd/C equivalents were 
added to the reaction in order to drive it to completion (N.B., the reaction was monitored by 6:1:0.01 
DCM:MeOH:NH4OH).  The crude product was filtered through celite and concentrated to dryness. 
0.086 g 34 was obtained at a yield of 67%, which was somewhat lower that the yield reported in the 
literature.1 0.091 g 35 was obtained at a yield of 72%, which was also lower than previously reported 
yields.1 It is noteworthy that both compounds were quite unstable owing to the primary amine that 
resulted from the deprotection reaction.  In fact, the first time the reaction was attempted with 32, the 
product (34) degraded from a rise in room temperature that took place when the laboratory's air-
conditioning unit was switched off.  Therefore, the second time the reaction was completed, the product 
was placed inside the freezer until the next step in the reaction scheme was attempted.
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Scheme 5. Deprotection of monoprotected intermediate.
2.3.5  Final Product Synthesis
For the final step in the reaction scheme, compounds 34 and 35 were reacted with an acidic 
“cap” through an amide coupling mechanism in order to ensure their stability when performing assays 
at room temperature (see scheme 1 for the cap's structure).  First, the cap was placed in 1 mL DMF 
with molecular sieves and under N2 protection to ensure anhydrous conditions.  Like in the previous 
amide coupling reaction, the presence of H2O would disrupt the formation of the acid-EDCI complex 
necessary for the reaction to proceed in a timely manner.  After one day, [1.5] equivalent HOBt and 
[1.5] equivalent EDCI were added to the reaction at 0 oC and the reaction was allowed to warm up to 
room temperature.  Then, 34 or 35 was mixed with 1 mL DMF and added dropwise to the reaction. 
After three days, the reaction was monitored by TLC (7:1:0.01 DCM:MeOH:NH4OH) to reveal that the 
amine starting material was no longer present in the reaction mixture.  There was a main product spot 
(UV and iodine active) present with lots of byproducts and remaining catalyst.  The reaction was 
filtered, concentrated to dryness and purified by column chromatography (10:1:0.01 
DCM:MeOH:NH4OH)  The reaction yield was quite low for both products, but this result had already 
been reported in the literature.1 0.030 g 22 was synthesized at a yield of 30%, and 0.030 g 23 was 
synthesized at a yield of 25%.
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Scheme 6. Amide-coupling reaction of intermediate and acidic cap.
Both products were coverted to hydrochloride salts and recrystallized in 9:0.1 diethyl 
ether:MeOH.  
3.  In Vitro Studies
3.1  Results from Calcium Mobilization Assays with Initial 21-Atom Bivalent Compound
In total, approximately 9 compounds were synthesized for the study of the CCR5-MOR 
heterodimer (N.B., this does not include the 3-position spacer and its maraviroc control, which were 
found to be less efficacious at binding to CCR5 and the CCR5-MOR heterodimer relative to the 4-
position spacer and its control).  Figure 11 shows the first 3 of these compounds, the 21-atom spacer 
and its two monovalent controls, which were synthesized by Dr. Yunyun Yuan.  These compounds were 
tested in either CCR5- or MOR- cells and cells expressing both CCR5 and MOR.
41
ONHO
OH
N
H
O
O
N
H
O
N
H
O
O
O
N
H
N N
N
N
HN H
O
F
F
N
H
O
O
N
H
O
N
H
O
O
O
N
H
N N
N
N
HN H
O
F
F
5
18
5
O
NHO
OH
N
H
O
O
N
H
O
N
H
O
O
O
N
H5
Figure 11.  Original 21-atom bivalent compound (18) with maraviroc and 6β-naltrexamine controls.
Calcium mobilization assays were chosen to test the functional activity of the compounds due to 
their simplicity.125 In these assays, GPCR signaling causes the release of intracellular calcium stores.125 
Ideally, the IC50's of these compounds should match both maraviroc and naltrexone, as this would 
indicate good inhibition at the CCR5 and MOR receptors.  Figure 12 shows a schematic representation 
of the mechanism behind the calcium mobilization assay.
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Figure 12.  Schematic representation of a calcium mobilization assay.  
The results for compound 18 in assays containing CCR5, MOR or the CCR5-MOR heterodimer 
are as follows.  In assays utilizing human acute lymphoblastic leukemia (MOLT-4) cells transfected 
with CCR5, 18 had an IC50 of 130 ± 28 nM, an approximately 60 fold-decrease in activity relative to 
maraviroc, which had an IC50 of 2.2 ± 0.31 nM.120  While this fold-decrease in activity is significant, it 
is expected given the attachment of maraviroc to a spacer and another molecule.  However, the 
maraviroc control containing just a spacer had a much larger decrease in activity relative to maraviroc, 
with an IC50 of 620 ± 36 nM (i.e., a 600 fold-decrease in activity).120 More maraviroc controls and 
spacer molecules would have to be synthesized and tested in order to see whether or not this significant 
fold-decrease was consistent with attaching a spacer to the 4-position of maraviroc.  
In chinese hamster ovarian (CHO) cells containing hMOR, 18 only had a slight fold-decrease in 
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activity relative to naltrexone.  18's IC50 was 40 ± 4.8 nM, whereas naltrexone had an IC50 of 8.9 ± 0.87 
nM (a fold-decrease of 4.5).120 The 6β-naltrexamine spacer had an IC50 of 17 ± 4.9 nM, or a fold-
decrease of 1.9, confirming that a spacer attached to the 6 position was tolerable.120 
Finally, in an assay containing CHO cells transfected with both CCR5 and MOR genes, 18 was 
found to have an IC50 of 17 ± 5.7 nM at the hMOR receptor, only a 3 fold-decrease from naltrexone.120 
This further confirms the tolerability of a spacer attached to the 6-position of naltrexone.  However, at 
the CCR5 receptor, the compound was found to have an IC50 of 6200 ± 250, a 350 fold-decrease 
relative to maraviroc.120 Thus, more compounds with modifications at the 4-position of maraviroc 
would have to be tested in order to verify its viability or lack thereof.   
Figure 13 contains the other six compounds synthesized and tested in calcium mobilization 
assays.  These compounds include both 19- and 23-atom bivalent compounds (20 & 21) along with 
their 6β-naltrexamine (22 & 23) and maraviroc (24 & 25) controls.  Dr. Yunyun Yuan synthesized 20, 
21, 24 and 25.  Thomas Raborg synthesized 22 and 23.  The maraviroc containing compounds were 
tested using MOLT-4 cells transfected with CCR5, whereas the 6β-naltrexamine compounds were 
tested using CHO cells transfected with hMOR.
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Figure 13. Two bivalent compounds of varying spacer length and their controls.
3.2 MOR-Radiobinding Assay
Before calcium mobilization assays were performed on the compounds in Figure 13, a binding 
assay was run in order to verify that the 6β-naltrexamine-containing compounds could bind to the 
MOR receptor at high affinity.  This assay was run by Dr. Yunyun Yuan using compounds synthesized 
by both Dr. Yuan and Thomas Raborg.  Table 5 shows the results of the MOR-radiobinding assay for 
the 6β-naltrexamine-containing compounds.  As one can observe, the bivalents (20 & 21) and their 6β-
naltrexamine controls (22 & 23) did not have significant fold-decreases in affinity relative to 
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naltrexone.  This indicates that all the compounds were relatively potent for the MOR receptor.
Table 5. MOR-radiobinding assay
Compound MOR  Ki (nM) Fold-decrease in Affinity 
Compared to Naltrexone
Naltrexone 0.7 ± 0.1 -
20 3.8 ± 0.55 5.4
22 0.78 ± 0.12 1.1
21 1.1 ± 0.08 1.6
23 6.5 ± 0.16 9.3
A CCR5-radiobinding assay also needs to be conducted in the future to test the relative 
potencies of each of the maraviroc-containing compounds.  This might help verify the calcium 
mobilization assay's result that attachments to the phenyl ring of maraviroc are not tolerated for CCR5 
binding.
3.3  CCR5-MOLT4 Calcium Mobilization Assay
First the bivalent compounds and their maraviroc controls were tested for CCR5 agonism and 
antagonism in assays utilizing MOLT-4 cells transfected with CCR5.  In assays testing for agonism, 
there was no apparent agonism of CCR5 for any of the molecules.  Prior to testing for antagonism, the 
MOLT-4 cells were transfected with a chimeric G protein, Gqi5, in order to stimulate calcium signaling. 
A range of concentrations was set up similar to the range of concentrations that gave accurate IC50's of 
the original 21-atom bivalent spacer and its maraviroc control.  Each assay well also contained a 
specific concentration of RANTES, a CCR5 agonist, in order to test the inhibition of calcium 
mobilization.  All compound concentrations were run in triplicate and tested three separate times.
Like for the 21-atom bivalent molecule (18) and its maraviroc control, the 19- and 21-atom 
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bivalents (20 & 21) and their maraviroc controls (24 & 25) also demonstrated decreased antagonism 
relative to maraviroc for CCR5 (Table 5).  Thus, it appears as if modifications to the phenyl ring of 
maraviroc are not well tolerated for CCR5-binding.  Therefore, future synthetic alterations to the 
bivalent compound may involve changing the spacer's point-of-attachment to maraviroc.
Table 6. Antagonism of calcium mobilization in RANTES-stimulated MOLT-4 cells
Compound CCR5 Antagonism IC50 (nM) Fold-decrease in Activity 
Compared to Maraviroc
Maraviroc 2.2 ± 0.3 -
20 2400 ± 620 1100
24 950 ± 34 430
21 540 ± 79 250
25 390 ± 51 180
A recent paper published the crystal structure of maraviroc bound to CCR5.  It was found that, 
contrary to a previously reported modeling study,121 the phenyl ring of maraviroc faces inward at the 
maraviroc binding pocket and has many favorable hydrophobic interactions with certain amino acid R 
groups.126 This fact demonstrates the implausibility of attaching the spacer to the phenyl ring of 
maraviroc, as doing so would significantly change its traditional inhibitory binding mode.  While this 
puts a damper on the research project this laboratory has been conducting, the purported binding mode 
of maraviroc introduces new locations to which a future spacer may be attached.  
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Figure 14.  Crystal structure of maraviroc bound to CCR5.126 
3.4  hMOR-CHO Calcium Mobilization Assay
MOR agonism and antagonism were also tested using calcium mobilization assays.  However, 
this time the targeted protein (i.e., hMOR) was transfected in CHO cells instead of MOLT-4 cells. 
Again, like in the MOLT-4 calcium assays, Gqi5 was transfected into the CHO cells to stimulate 
calcium mobilization upon agonist binding.125 The compounds demonstrated no agonism.  Using the 
MOR agonist DAMGO, the compounds were tested for their ability to inhibit calcium mobilization, 
and the results were tabulated in Table 6.
According to Table 6, the bivalent compounds (20 & 21) and their monovalent 6β-naltrexamine 
controls (22 & 23) did not contain significant fold-decreases in activity relative to the traditional MOR 
antagonist naltrexone.  The compound with the greatest decrease in activity, 22, only had a 32 fold-
decrease in activity relative to naltrexone.  This corresponds to a fold-decrease of only two orders of 
magnitude.  This demonstrates that the 6-position of the naltrexone molecule can tolerate numerous 
structural modifications and still be able to bind to MOR.  Future modifications on the bivalent 
compound can probably maintain the spacer at the 6-position of 6β-naltrexamine without worry of a 
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substantial decrease in activity for MOR. 
Table 7. Antagonism of calcium mobilization in DAMGO-stimulated hMOR-CHO cells.
Compound MOR Antagonism IC50 (nM) Fold-decrease in Activity 
Compared to Maraviroc
Naltrexone 2.9 ± 0.27 -
20 22 ± 5.6 7.6
22 92 ± 020 32
21 22 ± 3.7 7.6
23 41 ± 25 14
3.5  Conclusions from In Vitro Studies
Regardless of the decrease in activity for the CCR5 receptor, the bivalent compounds still need 
to be tested in calcium mobilization assays involving a cell line transfected with both CCR5 and MOR. 
While modifications to the phenyl ring of maraviroc are not tolerated for binding to CCR5, and 
therefore a new spacer molecule needs to be synthesized in order to produce better binding, testing 
these two new bivalent compounds in a cell-line containing both receptors may indicate which spacer 
length is optimal for simultaneous CCR5-MOR binding.  If either the 19-atom bivalent (20) or the 23-
atom bivalent (23) is significantly better than the 21-atom bivalent (18) at inhibiting calcium 
mobilization in cells containing both receptors, then future modifications to the spacer's point-of-
attachment to maraviroc may incorporate this change in spacer length.
4.  In Silico Studies
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4.1  Introduction to Conformational Analysis
A molecule can undergo spatial rearrangements that do not alter its basic chemical structure. 
The study of the differences between these rearrangements – called conformations – is called 
conformational analysis.126–128 These spatial rearrangements occur through changes in rotation around a 
single chemical bond that do not affect the bond's length or physical characteristics.  If a particular 
rotation around a single chemical bond produces interactions that are not favorable within a molecule, 
then the resultant conformation is not considered viable.126  The corollary to this is that if a rotation 
around a chemical bond does produce favorable interactions within a molecule, then the resultant 
conformation is deemed viable.  Since a receptor often interacts with a ligand only when that ligand is 
in a specific conformation, and since the number of viable conformations a molecule can undergo is 
limited, it is important to identify possible binding conformations.  Furthermore, since a molecule's 
external environment is subject to change (and it can undergo drastic changes), it is important to 
identify all viable conformations of a molecule independent of its external environment.126  
Using conformational analysis molecular modeling software, there are two important ways to 
identify viable conformations of a molecule.126 One way is through energy minimization, i.e., through 
rearranging the atoms of a molecule until it adopts a global minimum energy conformation.126  This 
method is based on the assumption that a molecule will adopt a conformation either identical or similar 
to its lowest energy state in reality.  When this method is adopted, a molecule will rearrange in a 
manner to produce the least torsional strain between atoms around a single chemical bond and also try 
to maximize intramolecular van Der Waals interactions.126  When this procedure is conducted, the 
product is a single molecule.  Given that this method may produce a conformation that is not viable for 
binding to a receptor, another method, termed systematic conformational search analysis, is sometimes 
required.126  Using this method, a set of rotatable bonds in a molecule is identified and those rotatable 
bonds are altered with respect to all other bonds in a molecule.126  In other words, each rotatable bond is 
50
altered and examined as a function to all other molecular bonds.  For each different conformation that 
is achieved as a result of a single chemical bond rotation, all internal distances are computed, and a 
conformation is rejected if the distance between the interacting species is greater than the sum of the 
van der Waals radii.126  By using this method, all viable conformers within a certain energy range of the 
global minimum are identified.  Unlike the global minimization analysis, the systematic conformational 
search analysis method produces a set of viable conformers that can exist in solution.  This method is 
useful in that it produces multiple viable conformations that can exist besides the global minimum.
4.2  Choosing a Conformational Analysis Software
Multiple molecular modeling programs exist for performing conformational analysis.  Among 
them are Systematic Conformational Search, Grid Search, Random Conformation Search, GA 
Conformational Search and Confort Conformational Analysis Modeling Software.126, 127  Methods such 
as Systematic Conformational Search, Grid Search, Random Conformation Search and GA 
Conformational Search rotate an individual chemical bond within a specified increment until a 
minimum energy is achieved.126, 127 Although these methods produce a set of viable conformations, they 
are not exhaustive and they are poor at calculating global minima.  Confort, on the other hand, has 
algorithms both for calculating global minima and producing a set of viable, diverse conformations that 
approximate a global minimum.126 Confort, therefore, was used in the following conformational 
analysis study rather than other methods.
There were two purposes regarding the conformational analysis study on the 19-, 21- and 23-
atom spacers: 1) to see if all three spacer had viable binding conformations (i.e., viable in the sense that 
the molecules could potentially bind to two different GPCR's simultaneously), and 2) to see if all three 
spacers adopted similar viable conformations.  Completion of the former objective could be used to 
hypothesize that the molecules actually bind to their target receptors simultaneously.  Completion of the 
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latter objective could be used to hypothesize that the 3 spacers can adopt identical binding 
conformations in solution and, therefore, any difference in binding between the three molecules is 
primarily because of spacer length (and not differences in conformation).
4.3  Molecular Building
All ligands used in the conformational analysis studies were built with standard bonds and 
angles using the molecular modeling software SYBYL-X 2.0.  The proper stereochemical arrangements 
were also assigned for each asymmetric carbon to ensure viability of results and uniform spatial 
arrangements between each spacer molecule. For the process of energy minimization (to establish a 
local minimum conformation for each small molecule), each small molecule was assigned Gasteiger-
Huckel charges and then minimized using the Tripos Force Field.  
4.4  Global Minimization Conformational Analysis
In order to identify viable conformations for the three spacer molecules, global minimization 
was conducted using Confort.  Again, this technique assumes that a molecule will adopt a conformation 
similar to its global minimum in actuality.128  However, before running the global minimum simulation, 
certain parameters were set in order to achieve optimal results.  First, the search was set to include 
analyses of all rotatable bonds and a maximum number of concurrently searched rotors.  Maximums of 
100 acyclic bonds, 20 ring system bonds and 10 single-ring bonds were defined.  Then, the precision of 
the results was set to .001 kcal/mol and Gasteiger-Huckel charges were applied.  The output file was set 
to include the the global minimum with 9 lowest-energy conformers approximating the global 
minimum.  After these parameters were set, the program was run for each spacer individually.
For the 19-, 21- and 23-atom spacers, each molecule adopted a “folded” conformation, one in 
which the spacer contorted to bring the maraviroc portion of the molecule in close proximity with the 
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6β-naltrexamine portion (see Figures 14, 15, and 16).  This makes sense because in order to achieve a 
global minimum a molecule has to contort in such a way as to allow maximum van der Waals 
interactions.  Thus, the molecules contorted at the center of the spacer, as this allowed the molecules' 
two groups (i.e., maraviroc and  6β-naltrexamine) to best engage in van der Waals interactions.  While 
this conformational change was similar in all three spacer molecules (thus producing similar global 
minimum conformations), it should be noted that this change did not produce a molecule conducive for 
binding to two different receptors.  If the maraviroc portion interacts with the naltrexamine portion in a 
manner similar to that seen in the three figures, then how is the molecule going to bind to two different 
receptors at once?  Furthermore, such a conformation would negate the importance of spacer length in 
binding to the two receptors.  From this study, it was obvious that a set of diverse conformers for each 
of the three molecules was necessary to verify that the molecules adopted plausible binding 
conformations.
Figure 15.  Global minimum of the 19-atom spacer.
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Figure 16.  Global minimum of the 21-atom spacer.
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Figure 17.  Global minimum of the 23-atom spacer.
4.5  DIVERSESET Conformational Analysis
DIVERSESET, a Confort algorithm used to generate sets of different and diverse 
conformations, was implemented in order to obtain plausible and viable conformations for each 
molecule.  When using DIVERSESET, it is still assumed that the the global minimum is the most likely 
conformation to exist in reality.  However, DIVERSESET also produces many low-energy 
conformations that approximate the global minimum and are therefore also likely to exist in solution. 
Like in the global minimization analysis, the search options were also set to include all rotatable bonds 
and a maximum number of concurrently searched rotors.  The precision was set to .001 kcal/mol and 
each molecule was assigned Gasteiger-Huckel electrostatics.  This time, however, the software was set 
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to generate a set of molecules (500 max.).  The output was further optimized by including a maximum 
output number of 500 diverse molecular conformations within 100 kcal/mol of the minimum.  The 
program was then run for all three spacer molecules individually (the Figures 17, 18, and 19 for 
results).
Unlike in the global minimization analysis, the DIVERSESET algorithm produced 
conformations for each spacer that allowed it to adopt an “elongated” spatial arrangement.  That is to 
say, many of the low-energy conformers could theoretically bind to both the hMOR receptor and CCR5 
receptor at once, unlike the 3 global minima generated from the global minimization analysis.  Looking 
at Figures 18, 19, and 20, in which 10 low-energy conformers were superimposed upon one another, we 
can see similar elongated conformations for all three spacers (elongated in the sense that the maraviroc 
and naltrexamine portions are kept separate from one another).  Because of the similar conformations 
shared by the three spacer molecules, it can be hypothesized that any differences in binding activity are 
attributable to the length of the spacer and not drastic differences in conformation.  Therefore, the 
DIVERSESET algorithm has produced results consistent with the two purposes of the conformational 
analysis study, i.e., to verify conformational similarity between the three spacers and to verify their 
viability in binding to two different receptors at once.
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Figure 18.  Diverse set conformational ensemble of the 19-atom spacer.
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Figure 19.  Diverse set conformational ensemble of the 21-atom spacer consisting.
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Figure 20.  Diverse set conformational ensemble of the 23-atom spacer
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5.  Experimental
5.1  Chemistry Intermediates
OH
N
O
HO N
37
(4R, 4aS, 7R, 7aR, 12bS)-3-(cyclopropylmethyl)-7-(dibenzylamino)-2,3,4,4a,5,6,7,7a-octahydro-1H-
4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol (37). Naltrexone, free base, (0.5 g, 0.001460 mol) 
was dissolved in 50 mL absolute EtOH.  Benzoic acid (1.1 eq, 0.18 g, 0.0001474 mol) was added and 
the mixture was allowed to stir for 30 minutes under N2 protection. 150 mL toluene was added to the 
flask with benzoic acid (1.1 eq, 0.18 g, 0.001474 mol), dibenzylamine (1.2 eq, 0.34 mL, 0.001812 mol) 
and a trace amount of p-toluenesulfonic acid. The reaction was refluxed for 24 hours under N2 
protection with a Dean-Stark trap to remove any H2O produced from the reaction. One hundred and 
fifty mL of toluene was added during the course of the day. One hundred mL EtOH, molecular sieves, 
and NaBH3CN (1.1 eq, 0.100 g, 0.001591 mol) were added and allowed to stir under N2 protection for 
24 hours. The mixture was then filtered, rotovaped and re-dissolved in dichloromethane with 3% 
aqueous NH4OH. The chloroform was rotovaped and (37) was recrystallized in 9:1 MeOH/H2O to give 
0.260 g at 35% yield. 1H NMR (400 MHz, CDCl3) δ 0.096 (m, 2H), 0.495 (m, 2H), 0.815 (m, 1H), 
1.230 (td, J = 10.4, 2.8 Hz, 1H), 1.409 (dd, J = 10.3, 2.4 Hz, 1H), 1.575 (m, 1H), 1.681 (m, 1H), 1.955-
2.119 (m, 2H), 2.170-2.244 (m, 1H), 2.327 (m, 2H), 2.475 (dd, J = 12.6, 5.8 Hz, 1H), 2.547-2.62 (m, 
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2H), 2.971 (m, 1H), 3.593 (d, J = 14.2 Hz, 1H), 3.874 (m, 2H), 4.693 (d, J = 7.8 Hz, 1H), 6.420 (d, J = 
8 Hz, 1H), 6.551 (d, J = 8 Hz) 7.819 (m, 2H), 7.279 (m, 5H), 4.222 (d, J = 7.2, 4H).
O
HO
N
OH
NH2
38
6β-naltrexamine (38). In a 250 mL hydrogenation flask, 37 (0.260 g, 0.0004990 mol) was dissolved in 
5 mL MeOH. 10% Pd/C (0.026 g, 10% w/w) and concentrated HCl (2 eq, 0.06 mL, 0.002036 mol) was 
added. The flask was placed on a hydrogenator at 60 psi H2 gas for 24 hours and monitored with TLC 
(10:1:0.01 DCM:MeOH:NH4OH). Once completed, the reaction mixture was filtered through celite and 
evaporated.  38 was recrystallized in 9:1 diethyl ether:MeOH to give a total of 0.199 g x2 
hydrochloride salt, giving a yield of 96%. 1H NMR (400 MHz, DMSO-d6) δ 0.41 (m, 1H), 0.51 (m, 
1H), 0.59 (m, 1H), 0.67 (m, 1H), 1.06 (m, 1H), 1.32 (m, 1H), 1.46 (d, J = 8.8 Hz, 1H), 1.78 (m, 1H), 
1.82 (d, J = 14.4 Hz, 1H), 1.99 (q, J = 12.5, Hz, 1H), 2.50 (m, 2H), 2.90 (m, 2H), 3.04 (d, J1 = 6.0 Hz, 
J2 = 18.8 Hz, 2H), 3.33 (m, 2H), 3.90 (d, J = 4.8 Hz, 1H), 4.68 (d, J = 7.2 Hz, 1H), 6.40 (brs, 1H), 6.67 
(d, J = 8.0 Hz, 1H), 6.80 (d, J = 8.0 Hz, 1H), 8.43 (m, 2H, exchangeable), 8.91 (brs, 1H, 
exchangeable), 9.58 (s, 1H, exchangeable).
H2N NH
O
O
28
(5-Amino-pentyl)-carbamic acid benzyl ester (28). In a 500 mL flask, 1,5-diaminopentane (1 eq, 1 g, 
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0.009804 mol) was dissolved in 250 mL DCM and stirred above a Dewar container containing 2-10 dry 
ice cubes and acetone.  Temperature was set to 0-5 oC. To the reaction mixture, Cbz-Cl (0.5 eq, 0.84 g, 
0.004924 mol) in 250 mL DCM was added dropwise for 12 hours while keeping the temperature at 0-5 
oC.  After the addition, the reaction mixture was evaporated to dryness and concentrated with a vacuum 
pump.  The crude product was then purified with column chromatography (5:1:0.01 
DCM:MeOH:NH4OH) to give 0.770 g 28 at 33% yield. 1H NMR (400 MHz, CDCl3) δ 1.345 (m, 2H), 
1.500 (m, 4H), 2.706 (t, J = 7.06 Hz, 2H), 3.204 (q, J = 6.4 Hz, 2H), 4.816 (s, 1H), 5.094 (s, 2H), 7.525 
(m, 5H).
N
H
O
OH2N
29
(9-Amino-nonyl)-carbamic acid benzyl ester (29). In a 500 mL flask, 1,9-diaminononane (1 eq, 1 g, 
0.006300 mol) was dissolved in 250 mL DCM and stirred above a Dewar container containing 2-10 dry 
ice cubes and acetone.  Temperature was set to 0-5 oC. To the reaction mixture, Cbz-Cl (0.5 eq, 0.49 g, 
0.002872 mol) in 250 mL DCM was added dropwise for 12 hours while keeping the temperature at 0-5 
oC.  After the addition, the reaction mixture was evaporated to dryness and concentrated with a vacuum 
pump.  The crude product was then purified with column chromatography (10:1:0.01 
DCM:MeOH:NH4OH) to give 0.440 g 29 at 24% yield. 1H NMR (400 MHz, CDCl3) δ 1.286 (broad s, 
10H), 1.489 (brs, 4H), 2.731 (t, J = 7.06 Hz, 2H), 3.187 (q, J = 6.4 Hz, 2H), 4.740 (s, 1H), 5.094 (s, 
2H), 7.348 (m, 5H).
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[(5-Benzyloxycarbonylamino-pentylcarbamoyl)-methoxy]-acetic acid (30). 28 (1 eq, 0.770 g, 0.003257 
mol) was dissolved in 18 mL THF above an ice-water bath at 0 oC.  Digylcolic anhydride (1 eq, 0.38 g, 
0.003276 mol) was added to the mixture, the water bath was removed and the reaction was allowed to 
continue at room temperature. The solution was stirred overnight and then evaporated to dryness. The 
crude product was recrystallized in 9:1 MeOH:diethyl ether to give 0.270 g at a yield of 30%. 1H NMR 
(400 MHz, CDCl3) δ 1.352 (m, 2H), 1.534 (m, 4H), 3.113 (t, J = 6.9 Hz, 2H), 3.239 (t, J = 6.9 Hz, 2H), 
4.045 (s, 2H), 4.171 (s, 2H), 5.057 (s, 2H), 7.308 (m, 5H). 
N
H
O
ON
H
O
O
O
HO
31
[(9-Benzyloxycarbonylamino-nonylcarbamoyl)-methoxy]-acetic acid (31). 29 (1 eq, 0.416 g, 0.001423 
mol) was dissolved in 10 mL THF above an ice-water bath at 0 oC.  Digylcolic anhydride (1.1 eq, 0.18 
g, 0.001442 mol) was added to the mixture, the water bath was removed and the reaction was allowed 
to continue at room temperature. The solution was stirred overnight and then evaporated to dryness. 
The crude product was recrystallized in 9:1 MeOH:diethyl ether to give 0.170 g at a yield of 30%. 1H 
NMR (400 MHz, CDCl3) δ 1.316 (brs, 10H), 1.512 (m, 4H), 3.095 (t, J = 6.9 Hz, 2H), 3.253 (t, J = 6.9 
Hz, 2H), 4.046 (s, 2H), 4.180 (s, 2H), 5.058 (s, 2H), 7.308 (m, 5H).
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32
benzyl(5-(2-(2-(((4R, 4aS, 7R, 7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,3,4,4a,5,6,7,7a-
octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl)amino)-2-
oxoethoxy)acetamido)pentyl)carbamate (32). 30 (1 eq, 0.145 g, 0.0004117 mol) was dissolved with 1 
mL DMF in a 5 mL flask.  To the solution, 1-hydroxybenzotriazole hydrate (1.5 eq, 0.083 g, 0.0006141 
mol), triethylamine (6 eq, 0.166 g, 0.001644 mol) and molecular sieves were added and the reaction 
was placed under N2 protection above an ice-water bath at 0 oC. N-(3-dimethylaminopropyl)-N'-
ethylcarbodiimide hydrochloride (1.5 eq, 0.096 g, 0.0006194 mol) was added and the water bath was 
removed, thus allowing the reaction to return to RT. 6β-naltrexamine (40) (1 eq, 0.171 g, 0.0004120 
mol) was dissolved in 1 mL DMF and added to the reaction dropwise. The reaction was monitored with 
TLC (10:1:0.01 DCM:MeOH:NH4OH) every 24 hours until completion and then filtered and 
evaporated to dryness. Column chromatography was conducted on the crude product (20:1:0.01 
DCM:MeOH, NH4OH) to obtain 0.165 g of 32 at a yield of 60%. 1H NMR (400 MHz, MeOD) δ .0414 
(brs, 2H), 0.752 (d, J = 7.6 Hz, 2H), 1.041 (s, 1H), 1.306 (m, 4H), 1.530 (m, 6H), 1.712 (m, 2H), 1.986 
(m, 1H), 2.529 (s, 2H), 2.744 (m, 2H), 2.989 (m, 2H), 3.118 (m, 2H), 3.204 (m, 2H), 3.725 (m, 2H), 
4.073 (s, 4H), 4.653 (s, 1H), 5.060 (s, 2H), 6.715 (m, 2H), 7.277 (m, 5H), 7.698 (t, J = 5.5 Hz, 1H).
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33
benzyl(9-(2-(2-(((4R, 4aS, 7R, 7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,3,4,4a,5,6,7,7a-
octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl)amino)-2-
oxoethoxy)acetamido)nonyl)carbamate (33). 31 (1 eq, 0.220 g, 0.0005392 mol) was dissolved with 1 
mL DMF in a 5 mL flask.  To the solution, 1-hydroxybenzotriazole hydrate (1.5 eq, 0.109 g, 0.0008074 
mol), triethylamine (6 eq, 0.220 g, 0.002178 mol) and molecular sieves were added and the reaction 
was placed under N2 protection above an ice-water bath at 0 oC. N-(3-dimethylaminopropyl)-N'-
ethylcarbodiimide hydrochloride (1.5 eq, 0.126 g, 0.0008129 mol) was added and the water bath was 
removed, thus allowing the reaction to return to RT. 6β-naltrexamine (40) (1 eq, 0.224 g, 0.0005398 
mol) was dissolved in 1 mL DMF and added to the reaction dropwise. The reaction was monitored with 
TLC (10:1:0.01 DCM:MeOH:NH4OH) every 24 hours until completion and then filtered and 
evaporated to dryness. Column chromatography was conducted on the crude product (30:1:0.01 
DCM:MeOH, NH4OH) to obtain 0.170 g of 33 at a yield of 43%. 1H NMR (400 MHz, MeOD) δ 0.265 
(m, 2H), 0.605 (m, 2H), 0.958 (m, 1H), 1.323 (brs, 12H), 1.477 (m, 6H), 1.616 (m, 2H), 1.952 (m, 1H), 
2.246 (m, 2H), 2.701 (m, 2H), 3.092 (s, 2H), 3.261 (s, 3H), 3.480 (s, 2H), 3.748 (s, 1H), 4.080 (s, 4H), 
4.561 (s, 1H), 5.057 (s, 2H), 6.665 (s, 2H), 7.332 (m, 5H), 7.753 (t, J = 5.5, 1H). 
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N-(5-aminopentyl)-2-(2-(((4R, 4aS, 7R, 7aR, 12bS)-3-(cyclopropylmethyl)-4a,9-dihyroxy-
2,3,4,4a,5,6,7,7a-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl)amino)-2-
oxoethoxy)acetamide (34). In a hydrogenation flask, 32 (1 eq, 0.165 g, 0.0002441 mol) was dissolved 
in 15 mL MeOH. To this solution, 10% Pd/C (0.0165 g, 10% w/w) was added. The flask was placed on 
a hydrogenator at 60 psi using H2 gas for 24 hours and monitored by TLC (7:1:0.01 
DCM:MeOH:NH4OH).  Once completed, the reaction mixture was filtered and then evaporated to 
dryness to give 0.086 g 34 at 67% yield.  1H NMR (400 MHz, MeOD) δ 0.153 (s, 2H), 0.526 (m, 2H), 
0.547 (s, 1H), 1.387 (m, 4H), 1.616 (m, 6H), 1.923 (m, 1H), 2.161 (m, 1H), 2.219 (m, 1H), 2.396 (m, 
2H), 2.624 (m, 2H), 2.736 (t, J = 6.4 Hz, 2H), 3.106 (m, 2H), 3.315 (s, 2H), 3.771 (m, 1H), 4.068 (s, 
4H), 4.504 (d, J = 7.6 Hz, 1H), 6.560 (d, J = 7.6 Hz, 1H), 6.643 (d, J = 7.6 Hz, 1H).
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N-(9-aminononyl)-2-(2-(((4R, 4aS, 7R, 7aR, 12bS)-3-(cyclopropylmethyl)-4a,9-dihyroxy-
2,3,4,4a,5,6,7,7a-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl)amino)-2-
oxoethoxy)acetamide (35) In a hydrogenation flask, 33 (1 eq, 0.160 g, 0.0002186 mol) was dissolved in 
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15 mL MeOH. To this solution, 10% Pd/C (0.0160 g, 10% w/w) was added. The flask was placed on a 
hydrogenator at 60 psi using H2 gas for 24 hours and monitored by TLC (7:1:0.01 
DCM:MeOH:NH4OH).  Once completed, the reaction mixture was filtered and then evaporated to 
dryness to give 0.091 g 35 at 72% yield.  1H NMR (400 MHz, MeOD) δ 0.171 (m, 2H), 0.534 (d, J = 
7.6 Hz, 2H), 0.879 (m, 1H), 0.896 (m, 12H), 1.357 (m, 6H), 1.576 (m, 1H), 2.436 (m, 2H), 2.676 (m, 
2H), 2.839 (t, J = 3.5 Hz, 1H), 3.119 (m, 2H), 3.346 (s, 2H), 3.749 (m, 1H), 4.110 (s, 4H), 4.517 (d, J = 
7.6 Hz, 1H), 5.481 (s, 4H), 6.628 (m, 2H), 7.352 (m, 1H).
Final Compounds
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5-carbon opioid monovalent compound (22). Methycarbamoylmethoxy acetic acid (1 eq, 0.024  g, 
0.0001622 mol) was dissolved with 1 mL DMF in a 5 mL flask.  To the solution, 1-
hydroxybenzotriazole hydrate (1.5 eq, 0.031 g, 0.0002296 mol), triethylamine (6 eq, 0.061 g, 
0.0006040 mol) and molecular sieves were added and the reaction was placed under N2 protection 
above an ice-water bath at 0 oC. N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (1.5 
eq, 0.035 g, 0.0002258 mol) was added and the water bath was removed, thus allowing the reaction to 
return to RT. 34 (1 eq, 0.086 g, 0.0001632 mol) was dissolved in 1 mL DMF and added to the reaction 
dropwise. The reaction was monitored with TLC (7:1:0.01 DCM:MeOH:NH4OH) every 24 hours until 
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completion and then filtered and evaporated to dryness. Column chromatography was conducted on the 
crude product (10:1:0.01 DCM:MeOH, NH4OH) to obtain 0.030 g of 22 at a yield of 30%. 1H NMR 
(400 MHz, MeOD) δ 0.525 (s, 2H), 0.747 (m, 2H), 1.119 (s, 1H), 1.404 (brs, 2H), 1.670 (m, 8H), 2.019 
(m, 1H), 2.549 (m, 2H), 2.716 (s, 4H), 2.882 (m, 2H), 3.117 (m, 2H), 3.269 (m, 4H), 3.721 (s, 1H), 
4.042 (s, 4H), 4.080 (s, 4H), 4.715 (d, J = 7.6 Hz, 2H), 6.747 (s, 2H). 13C NMR (400 MHz, MeOD) δ 
3.48, 6.25, 6.90, 24.55, 24.67, 25.21, 25.95, 28.94, 30.05, 31.18, 39.92, 39.97, 47.62, 54.41, 58.87, 
64.40, 71.39, 71.50, 71.64, 91.89, 119.72, 121.02, 121.85, 130.75, 143.15, 143.80, 171.75. IR (ATR, 
cm-1) vmax: 3274, 2933, 1644, 1549, 1530, 1455, 1373, 1323, 1185, 1124, 1034, 986, 917, 881, 856, 799. 
MS (ESI) m/z found, 672 (M + H)+, mp: 115 – 118 oC.
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9-carbon opioid monovalent compound (23). Methycarbamoylmethoxy acetic acid (1 eq, 0.023  g, 
0.0001554 mol) was dissolved with 1 mL DMF in a 5 mL flask.  To the solution, 1-
hydroxybenzotriazole hydrate (1.5 eq, 0.032 g, 0.0002370 mol), triethylamine (6 eq, 0.065 g, 
0.0006435mol) and molecular sieves were added and the reaction was placed under N2 protection above 
an ice-water bath at 0 oC. N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (1.5 eq, 
0.037 g, 0.0002387 mol) was added and the water bath was removed, thus allowing the reaction to 
return to RT. 35 (1 eq, 0.091 g, 0.0001560 mol) was dissolved in 1 mL DMF and added to the reaction 
dropwise. The reaction was monitored with TLC (7:1:0.01 DCM:MeOH:NH4OH) every 24 hours until 
completion and then filtered and evaporated to dryness. Column chromatography was conducted on the 
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crude product (10:1:0.01 DCM:MeOH, NH4OH) to obtain 0.030 g 23 at a yield of 25%.  1H NMR (400 
MHz, MeOD) δ 0.227 (s, 2H), 0.600 (m, 2H), 0.927 (s, 1H), 1.339 (brs, 10H), 1.536 (m, 8H), 1.940 (m, 
1H), 2.292 (s, 2H), 2.443 (s, 2H), 2.816 (m, 5H), 3.118 (m, 2H), 3.298 (m, 4H), 3.7501 (m, 1H), 4.027 
(s, 4H), 4.071 (d, J = 4.4 Hz, 4H), 4.801 (d, J = 7.6 Hz, 1H), 6.610 (d, J = 7.6 Hz, 1H), 6.665 (d, J = 
7.6 Hz, 1H). 13C NMR (400 MHz, MeOD) δ 4.06, 4.80, 23.74, 25.30, 25.89, 27.90, 27.92, 27.96, 30.26, 
30.42, 30.44, 30.48, 31.23, 40.08, 40.11, 52.49, 60.01, 60.04, 63.89, 71.40, 71.44, 71.50, 71.53, 71.56, 
71.58, 71.66, 92.73, 118.78, 120.27, 124.89, 132.06, 142.15, 143.75, 171.49, 171.51, 171.57, 172.17. 
IR (ATR, cm-1) vmax: 3273, 3078, 2926, 2853, 1651, 1548, 1503, 1454, 1374, 1322, 1258, 1185, 1126, 
1035, 987, 916, 883, 857, 799, 747, 699. MS (ESI) m/z found, 728 (M + H)+, mp: 112 – 115 oC.
5.2  Biology Methods
5.2.1  hMOR Competitive Radioligand Binding Assay
The affinity and selectivity of the novel bivalent compounds and their controls were determined 
using a competitive radioligand binding assay.  In this assay, the concentration of radioligand (i.e., 
tritiated naloxone) was fixed around its Kd value and its binding with respect to hMOR was tested by 
adding varying concentrations of drugs.  The IC50 values of the bivalents and controls were obtained 
from Hill plots and analyzed by linear regression.  The Ki values were calculated from the IC50 using the 
Cheng-Prusoff equation.
The assay was performed in triplicates with a fixed protein concentration of 30 µg.  The total 
assay volume was 500 µL with TME buffer.  Each assay rack included total binding, non-specific 
binding and drug-competition binding tubes.  The total binding tubes contained the buffer, radioligand 
and protein.  The non-specific binding tubes included all of the total binding components as well as 
excess unlabeled drug.  A maximum of two drugs were tested at seven different concentrations per 
rack.  These tubes contained the buffer, bivalents (or controls), radioligand and protein.  Of note, the 
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drug concentration is each tube was multiplied by ten times in order to take the ten-fold dilution in each 
tube into account.  After the first assay, the drug concentrations were optimized in order to get better 
IC50 values.  It is also important to note that protein-bound tritiated radioligand was separated from 
unbound radioligand by a specialized type of fibrous filter paper, and the radioactive decay of the 
unbound radioligand was measured using a scintillation counter.
5.2.2  Calcium Mobilization Assays
5.2.2.1  hMOR-CHO Cells
hMOR-CHO cells were transfected with Gqi5 pcDNA1 and incubated for 6 hours at 37oC and 
5% CO2.  After the 6-hour interval, the cells were detached from the plate with trypsin and transferred 
to a clear bottom, black 96-well plate at 20,000 cells per well.  The cells were supplemented with 
DMEM/F-12 media containing 5% fetal bovine serum, 100 µg/mL penicillin, 100 µg/mL streptomycin 
and 0.25 mg/mL hygromycin B.  24 hours after the transfection the growth media was discarded and 
the wells were washed with 100 µL/well of 50:1 HBSS:HEPES assay buffer.  The cells were then 
incubated with 55 µL/well of Fluo-4 loading buffer [30 µL 2 µM Fluo4-AM and 84 µL 2.5 mM 
probenacid in 5.5 mL assay buffer] for 30 minutes.  Varying concentration (in triplicate) of ligands and 
controls were added to the wells to bring the total volume to 80 µL/well, and the well-plate was again 
incubated, this time for 15 minutes.  The plate was then read on a FlexStation3 microplate reader 
(Molecular Devices) at 494/516 ex/em for a total of 2 minutes.  After 15 second of reading, 20 µL of 
1.25 µM DAMGO in assay buffer, or assay buffer alone for the control wells, was added to bring the 
total volume of each well up to 100 µL.  The changes in Ca2+ mobilization were monitored using 
SoftMaxPro software.  Non-linear regression curves and IC50 values were generated using GraphPad 
Prism software.  This experiment was performed three times to get an average of each IC50 value.
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5.2.2.2 CCR5-MOLT-4 Cells
CCR5-MOLT-4 cells were transfected with Gqi5 pcDNA1 and maintained in RPMI 1640 media 
supplemented with 10% fetal bovine serum, 100 µg/mL penicillin, 100 µg/mL streptomycin and 1 
mg/mL G418 before being incubated for 48 hours at  37oC and 5% CO2.  48 hours after the 
transfection, the 2.5 million cells were spun down and diluted in 8 mL of 50:1 HBSS:HEPES assay 
buffer.  The cells were then plated at 25,000 cells per well (80 µL of diluted cell solution) into a clear 
bottom, black 96-well plate.  Then, 50 µL/well of Fluo-4 loading buffer [40 µL 2 µM Fluo4-AM and 
100 µL 2.5 mM probenacid in 5 mL assay buffer] was added to bring the volume of each well up to 130 
µL.  The plate was incubated for 45 minutes, after which varying concentrations (in triplicate) of 
ligands and controls were added to the wells to bring the total volume up to 180 µL.  The plate was 
then incubated for an additional 15 minutes.  The plate was then read on a FlexStation3 microplate 
reader (Molecular Devices) at 494/516 ex/em for a total of 1.5 minutes.  After 15 second of reading, 20 
µL of 200 nM RANTES in assay buffer, or assay buffer alone for the control wells, was added to bring 
the total volume of each well up to 200 µL.  The changes in Ca2+ mobilization were monitored using 
SoftMaxPro software.  Non-linear regression curves and IC50 values were generated using GraphPad 
Prism software.  This experiment was performed three times to get an average of each IC50 value.
5.3  Computational Methods
5.3.1  Small Molecule Construction
All ligands used in the conformational analysis studies were built with standard bonds and 
angles using the molecular modeling software SYBYL-X 2.0.  The proper stereochemical arrangements 
were also assigned for each asymmetric carbon to ensure viability of results and uniform spatial 
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arrangements between each spacer molecule. For the process of energy minimization (to establish a 
local minimum conformation for each small molecule), each small molecule was assigned Gasteiger-
Huckel charges and then minimized using the Tripos Force Field.  
5.3.2  Global Minimization Conformational Analysis
The molecules were first drawn in the SYBYL-X 2.0 molecular modeling program and then, 
after assigning them Gasteiger-Huckel charges, minimized using the Tripos Force Field.  The 
parameters for the global minimization conformational analysis studies were then set up using Confort 
conformational analysis modeling software, a program developed by Professor Robert Pearlman and 
Dr. Renzo Balducci.128  For the global minimization of each small molecule, the search options were 
optimized to give accurate and viable results.  First, the search was set to include the conformations of 
all rotatable bonds.  Then, the maximum number of concurrently searched rotors was set to 100 for 
acyclic bonds, 20 for bonds included in ring systems and 10 for bonds in single rings (these parameters 
were required to ensure accuracy of results).  Gasteiger-Huckel electrostatics were assigned to each 
molecule and the precision of results was set to .001 kcal/mol.  The maximum output of low energy 
conformers was set to 10 in order to produce a global minimum and 9 low-energy conformers within 
approximately 10 kcal/mol of the global minimum.  The program was then run and the results were put 
into a SYBYL spreadsheet, organizing each conformer by energy relative to the global minimum. 
After each of the conformers were analyzed, the global minimum conformer was placed into the 
SYBYL molecular area and a snapshot of it was taken.
5.3.3  Diverse Conformer Subset Conformational Analysis
The molecules were first drawn in the SYBYL-x 2.0 molecular modeling software and then 
minimized using the Tripos Force Field.  Each molecule was assigned Gasteiger-Huckel charges before 
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energy minimization.  The parameters for the diverse conformer subset conformational analysis studies 
were then set up using Confort conformational analysis software.128  In developing a diverse conformer 
subset for each molecule, the search options were optimized to give repeatable, accurate and viable 
results.  Like in the global minimization conformational analysis studies, the search was set to include 
all conformations of rotatable bonds.  The maximum number of concurrently searched rotors was set to 
100 for acyclic bonds, 20 for bonds included in ring systems and 10 for bonds in single rings.  Again, 
these parameters were required to produce accurate results.  Gasteiger-Huckel electrostatics were 
assigned to each molecule and the precision of results was set to .001 kcal/mol.  Also included in the 
search options was a maximum conformer output of 500 low-energy conformations.  The output 
settings were further modified to include a maximum of 500 diverse low-energy conformers (i.e., any 
conformer nearly identical in spatial arrangement and energy to another already-produced conformer 
would be rejected from the search results) within at least 100 kcal/mol of the lowest-energy conformer. 
The program was then run and the results were put into a SYBYL spreadsheet, organizing each 
conformer by energy relative to the lowest-energy conformer.  A subset of 10 low-energy conformers 
within 20 – 30 conformers of the lowest-energy conformer were then extracted from the spreadsheet 
and placed into the SYBYL molecular area.  These 10 conformers were aligned according to specific 
atoms within the molecule to give a comparative analysis.  Once this was completed, a snapshot of the 
superimposed molecules was taken.
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